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Central pulse pressure (cPP), a product of ventricular-arterial interaction, is an important 
determinant of cardiovascular outcomes in hypertension. The aim of this thesis is to advance 
the understanding of pulsatile haemodynamics and to explore mechanisms that may 
selectively reduce cPP.  
The conventional view is that cPP comprises a component determined by the direct 
interaction of myocardial contraction with the impedance of the proximal arterial tree (closely 
related to pulse wave velocity, PWV) and a component ‘augmentation pressure’ generated by 
pressure wave reflections from muscular conduit arteries. Surprisingly little is known 
regarding regulation of conduit artery tone despite its potential influence on cPP. In the first 
part of this thesis, muscular large arterial tone was examined using a human forearm blood 
flow model. Vasoactive substances were infused locally into the brachial artery and 
vasodilator responses of the radial artery, as a muscular conduit artery, and forearm resistance 
microvasculature were examined. Nitric oxide donors, in particular, glyceryl trinitrate (GTN) 
were found to have the most selective action on conduit arteries compared to other 
vasodilators. In the second part of the thesis, I examined whether the action of GTN to reduce 
augmentation pressure could be accounted for by this selective dilation of muscular arteries. 
GTN was given systemically and by intra-coronary infusion in patients undergoing cardiac 
catheterisation. Invasive aortic blood pressure and flow velocity were analysed in the time 
domain by wave intensity analysis. This allows separation of pressure into a forward 
component generated by myocardial contraction and a backward component generated by 
‘reflection’ from the peripheral arterial tree. A surprising finding was that changes induced by 
GTN were mainly attributable to a reduction in forward rather than backward pressure waves. 
That this resulted from a change in myocardial contractility was confirmed by local intra-
3 
 
coronary injection of GTN.  The final part of the thesis examines the relative contribution of 
forward and backward pressure waves in hypertension. An elevated cPP in hypertensive 
compared to normotensive subjects was accounted for primarily by an increased forward 
pressure wave. That this was due to increased myocardial contractility was confirmed by 
examining whether the pattern of wave intensity seen in hypertension could be reproduced, in 
normotensive subjects, by the inotrope dobutamine (when compared to the vasoconstrictor 
norepinephrine used as a control). This thesis thus provides novel insight into a) regulation of 
conduit artery tone, and b) pulsatile haemodynamics, highlighting the contribution of left 
ventricular ejection characteristics in determining pressure augmentation and cPP.   
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1.1 Hypertension  
Hypertension affecting almost 1 in 3 of the population is the major preventable risk factor for 
premature disability and mortality globally.
1, 2
 Symptoms are usually absent, at least in the 
early stages; therefore it is often underdiagnosed and undertreated despite the unequivocal 
evidence supporting the health and economic benefit for blood pressure lowering in 
hypertension.
3-8
 Other than lifestyle modifications such as reducing salt intake and weight 
management, the mainstay treatment of hypertension remains pharmacological and most anti-
hypertensive drugs are vasodilators.
9-11
 Early epidemiological studies confirmed the 
importance of elevated peripheral resistance as the hallmark haemodynamic change in 
hypertension
12
 and unsurprisingly the diagnostic criteria and therapeutic focus was on 
diastolic blood pressure and peripheral resistance until relatively recently.
13
 Pharmacological 
research is still mainly centred on the effects of vasodilators on resistance arterioles 
determining peripheral resistance.
14
 Despite a longstanding appreciation of associations 
between arterial stiffening and hypertension
15
, the importance of aortic stiffness and systolic 
and pulse pressure in predicting cardiovascular outcome have only become evident from 





1.2 Components of blood pressure 
Non-invasive brachial artery blood pressure measurements form an important part of 
cardiovascular risk assessment in everyday clinical practice. The systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) values obtained from these measurements 
represent the peak and the nadir of the brachial arterial pressure waveform. An alternative 
16 
 
way of characterising the waveform, which may offer more insight into the haemodynamics, 
is by steady state component, mean arterial pressure (MAP), the pressure averaged over one 
cardiac cycle and the pulsatile component (PP), the difference between SBP and DBP.
18
 SBP 
and PP are dependent on both MAP and DBP with the exact relation being dependent on the 
form of the pulse wave but MAP is closer to DBP than SBP, so that SBP is influenced more 
by the PP, than is DBP. PP represents the pulsatile load exerted on the heart and large arteries 
and increases along the length of large arteries – a phenomenon termed pulse pressure 
amplification.
18
 Thus in health brachial artery PP (and SBP) may be 20mmHg higher than the 
aortic SBP.
19
 The steady state blood pressure components DBP and MAP, however stay 
relatively constant with a small fall in MAP of 1-2 mmHg in the peripheral circulation.
20
 
DBP has traditionally been viewed as the most important clinical parameter in hypertension 
as it is closely related to total peripheral resistance (TPR), an increase in which is thought to 
be the hallmark of hypertension. 
 
1.3 Effect of ageing on blood pressure components 
The Framingham study showed components of blood pressure change differently with age.
21
 
SBP increases approximately linearly with age. DBP, however reaches its maximum between 
50-60 years and falls thereafter. Consequently pulse pressure rises steeply from this age 
onwards. The increase in pulsatility with ageing is thought to be principally related to arterial 
stiffening, in particular aortic stiffening.
18, 21-24
 The cyclical mechanical stress exerted on the 
proximal aorta over time is thought to lead to fracturing of elastin, abnormal deposition of 
collagen and calcification. This reduces the cushioning function of the aorta to store energy in 
systole for peripheral run off during diastole. This in part explains the continue rise of SBP 
and a fall in DBP with ageing.
18, 22









 and end stage renal failure
28
, age-related aortic 
stiffening is thought to be accelerated, exacerbating the age-related increase in PP. 
 
1.4 Isolated systolic hypertension  
A number of epidemiological surveys of middle aged and elderly people published since the 
1980s have confirmed the importance of brachial PP widening as a strong independent 
predictor of cardiovascular events and mortality.
29-41
 Isolated systolic hypertension (ISH), 
defined by the European Society of Hypertension (ESH) guidelines as DBP <90mmHg and 
SBP >140mmHg, is the most common type of hypertension from middle age onwards.  In the 
NHANES III survey (The National Health And Nutrition Examination Survey) 75% of 
subjects with hypertension were aged over 50 years and 80% of these patients had ISH, 
demonstrating that widened PP is a highly prevalent in an ageing population with 
hypertension.
42
 Despite this there have been few therapeutic trials addressing the selective 
reduction in SBP and PP to reduce cardiovascular mortality. This may be due to the lack of 
molecules targeting specific mechanisms e.g. aortic stiffness and lack of drugs to selectively 
lower SBP compared to DBP.
3, 43,44
 In the context of ISH, there is a theoretical disadvantage 
in attempting to control systolic pressure with vasodilators, since diastolic pressure will fall 




1.5 Central blood pressure (CBP) 
Brachial SBP (bSBP) and DBP (bDBP) measurements are the current gold standard for the 
diagnosis of hypertension.
46
  Over the past decade emerging epidemiological data suggests 
that central measures of blood pressure and other CBP waveform indices taken from either 
18 
 
invasively measured or non-invasively derived aortic blood pressure waveform have an 
independent predictive value in cardiovascular risk assessment.
47
 Whether CBP indices have 
unquestionable advantages over brachial measurements is less clear. The 2013 ESH guideline 
does not recommend routine measurement of central haemodynamic indices in clinical 
practice, except for a potential role in assessing ISH in young patients. However it 
acknowledges their fundamental role in aiding the understanding of the haemodynamic 
mechanisms and therapeutics of hypertension.
10
 CBP indices are potentially important in the 
study of pulsatile haemodynamics because central pulse pressure (cPP) is what vital organs 
such as the brain, the heart and the kidney are exposed to not bPP.
18, 48, 49
 Since pulse pressure 
amplification may vary between subjects the assessment of central pulsatility by bPP may be 
inaccurate.
48, 50
  Furthermore, different classes of anti-hypertensive drugs appear to have 
differential effects on central and peripheral blood pressure measurements with consequent 




1.6 Pulse wave analysis  
The clear advantages of using bSBP and bDBP values in clinical practice are their established 
use and relative ease with which they may be derived using modern oscillometric methods. 
However bSBP and bDBP values alone provide an incomplete characterisation of 
haemodynamics as they represent the peak and nadir of the pressure at the brachial artery.
56
 
The introduction of commercially available high fidelity tonometers has advanced the field of 
pulse wave analysis (PWA) a great deal as they allow non-invasive recording of an arterial 
pressure waveform, which can then be calibrated from bSBP and bDBP. Tonometry is 
usually performed at the radial artery and it has been shown that a generalised transfer 
function (GFT) can be applied to a radial waveform to obtain a central aortic waveform with 
19 
 
reasonable precision. Alternatively, tonometry can be performed at the carotid artery which, 
because of its close proximity to the aorta, provides a waveform that closely resembles the 
aortic waveform. A number of indices to describe the central aortic pulse contour are shown 
in figure 1. 
 
 
Figure 1: An aortic pressure waveform can be measured invasively or estimated non-
invasively by radial tonometry via a transfer function. AP = augmentation pressure, the 
height above the first systolic shoulder; PP = pulse pressure; P1 = pressure at the first systolic 
shoulder above diastolic pressure; P2 = pressure at the second systolic shoulder above 




These indices provide a description of the pressure pulse contour and are thought to 
relate to ventricular and arterial properties. P1, the first shoulder above the diastolic pressure, 
is thought to be generated by a forward pressure wave from left ventricular ejection. P1 also 
20 
 
corresponds to peak blood flow velocity within a cardiac cycle and TR is thought to be the 
point at which the forward pressure wave generated by ventricular contraction coincides with 
a backward pressure wave caused by pressure reflected backwards from the peripheral 
arterial tree. Augmentation pressure (AP), the difference between pressure at the second 
shoulder (P2) and P1 and augmentation index (AIx), the percentage ratio of AP to cPP are 
thought to relate the magnitude and timing of pressure wave reflection.
18
 However this classic 
interpretation of AIx as a marker of pressure wave reflection has been challenged by a 
number of authors.
58-62
 Regardless of the mechanism and perhaps the meaning of AIx, the 
index itself has been shown in a meta-analysis to have independent predictive value for 
cardiovascular events and all-cause mortality.
47
 In addition the majority of the age-related 
increase in cPP is accounted for by an increase in AP and thus AP is a potential target for 
therapeutic intervention.
56, 63
 AP and AIx is thought to be influenced by a number of factors 
which include age, heart rate, height, ethnicity, aortic tapering and the pattern of left 
ventricular dynamics.
18, 46, 64-71
 Crucial to the accurate estimation of AP/AIx is the 
identification of TR or P1. Some investigators use the first systolic shoulder to mark the 
period of TR and P1 where others use the inflection point.
18, 72, 73
 The correct identification of 
TR, P1 and AIx is further complicated by physiological variation of the aortic pressure 
waveform. Murgo et al
72






Figure 2: Types of aortic pressure waveform as described by Murgo et al 
72
. Both type A and 
B waveforms are defined by P2>P1. Type A waveforms have AIx >12% and Type B have 




 have subsequently added a Type D waveform to this 
classification. A type D waveform is defined by a pressure pulse in which no inflection point 
can be identified. Figure 2 illustrates the importance of the methodology used to identify P1 
and TR as the results can varied widely, especially for Type D waveforms.
18, 61
 Type C 
waveforms are commonly seen in young healthy individuals. With ageing, the contour of the 
waveforms appear to progress from C to A, which is thought to be principally due to 
stiffening of large elastic arteries but changes in left ventricular dynamics and/or 
microvasculature are also potentially important.
22, 57
 Type D waveforms are reported in older 




1.7 Haemodynamic interpretation of the pressure pulse 
It is clear that the pressure pulse contour contains vital information on ventricular and 
vascular functions and therefore much effort has been devoted to model the pressure pulse in 
22 
 
order to establish its haemodynamic determinants. Currently the wave propagation model 
18
 
is the most widely accepted explanation for the pressure pulse. It is a one dimensional model 
describing wave travel in the forward and backward plane. A forward pressure wave (FPW), 
generated by left ventricular contraction travels distally along the aorta and its tributaries at a 
given speed termed pulse wave velocity (PWV). PWV is closely related to aortic 
characteristic impedance (Zc) which determines the ratio of forward pressure wave to flow in 








Where ρ = blood density and D = vessel diameter. Since blood density remains 
constant Zc is mainly determined by PWV and vessel diameter (D). PWV is directly 
proportional to the elastic modulus of blood vessels, a measure of stiffness, as demonstrated 







Where PWV = pulse wave velocity Einc = Young’s elastic modulus of arterial wall, h 
= arterial wall thickness, ρ = blood density, D = vessel diameter. It is evident from the above 
equations that both Zc and PWV are closely related to the contractile status and the intrinsic 
stiffness of the arterial wall. As the FPW propagates along the arterial tree, it encounters a 
backward pressure wave (BPW) generated by wave reflection at sites of impedance mismatch 
within the vascular tree
18
. Impedance mismatch is due to elastic and geometric tapering of 
arteries and arterial branching sites.
18, 72, 74
 Elastic tapering corresponds to the increase in 
proportion of vascular smooth muscle and collagen fibres in the extracellular matrix of the 
23 
 
arterial wall when moving distally away along the arterial tree away from the aortic root, thus 
smaller arteries are physiologically ‘stiffer’ in comparison to elastic large arteries. Geometric 
tapering is the gradual decrease in arterial diameter further along the arterial tree. Pressure 
wave reflection, therefore, does not only originate at distinct arterial branching points but is a 
continuous process along the arterial tree. Multiple BPW are thought to integrate to form a 






Figure 3: Type A aortic pressure waveform decomposed into forward (red) and backward 
(blue) pressure components. The forward pressure wave generated from left ventricular 
contraction integrates with the backward pressure wave at early systole therefore augmenting 
the pressure wave to form the final aortic pressure pulse (black).    
24 
 
The overall pressure waveform is the sum of the FPW and BPW and can be 
decomposed into FPW and BPW if pressure and flow are measured simultaneously as 
described in chapter 2. The amplitude as well as the timing of the BPW arrival at the 
proximal aorta is thought to determine the type of pressure waveform.
72
 In youth the Type C 
aortic pressure waveform is attributed to the arrival of BPW at late systole and early diastole, 
hence supporting coronary perfusion pressure during diastole. An increase in PWV as a result 
of aortic stiffness, is thought to lead to an earlier return of the BPW in systole. This widens 
the cPP and changes the morphology of the waveform (from Type C to Type A) resulting in 
an increase in afterload and a reduction in coronary perfusion pressure.
18, 75, 76
 As mentioned 
previously AP, the pressure above P1 of the pressure pulse, is thought to represent the 
integration of FPW and BPW, hence AP is thought to be a measure of wave reflection. 
Moreover, the increase in AP has been shown to drive the increase in cPP with ageing and 
other pathological processes
46, 71, 77, 78
, which leads to the hypothesis that pressure wave 
reflection is an important determinant of pulsatility within the cardiovascular system.
18
 In the 
peripheral circulation, pressure wave reflection could also potentially explain the 
phenomenon of PP amplification.
50
 In health the geometric and elastic tapering of the 
vascular tree leads to a regional variation of PWV (stiffness) with distal arteries 
‘physiologically stiffer’ than proximal arteries. This phenomenon leads to an earlier arrival of 
BPW in the distal muscular arteries compared to elastic arteries nearer to the heart, which 
results in a wider PP progressively from the aortic root towards the distal end of the muscular 
conduit arteries. With aortic stiffening, the magnitude of PP amplification reduces and this 






Within the arterial tree, the junction of the muscular conduit arteries – and resistance 
arteries is proposed to be the main site of pressure wave reflection by O’Rourke and 
colleagues.
18
 This stems from the observation that a rapid rise in peripheral resistance 
together with a fall in pressure occur over a very short distance within this region of the 
arterial tree, creating a concentrated area of impedance mismatch. In addition vasodilators 
acting on these vessels can reduce pressure wave reflection
84-88
 further supporting the 
potential significance of this region of the vascular tree in influencing pressure wave 
reflection. The main anatomical site for pressure wave reflection however remains elusive. It 
is thought that the distal aorta could be a discrete site of pressure wave reflection. However 
mechanistic studies designed to localise the exact anatomical site of pressure wave reflection 
have so far created conflicting results with no definitive site located.
18, 24, 58, 59, 61, 72, 89-92
 This 
may be because the assumptions applied to the estimation of the timing and distance of 
effective reflection site may be too simplistic for the human vascular tree.
91
  
The location of the site of effective pressure wave reflection is one of the many 
questions still to be explored regarding our current understanding of pressure wave 
propagation and its physiological contribution in determining pulsatile haemodynamics.
59
 
The other major criticism of the wave propagation model is the incomplete explanation of the 
interaction of the FPW and BPW during diastole and the failure to consider the Windkessel 
or cushioning effect of large arteries.
93
 The traditional two element Windkessel model has 
been updated since it was first described by Frank to account for the shortcoming in 
modelling the pressure pulse during systole.
94
 However, the major disadvantage of this model 
is its failure to incorporate wave propagation in the vascular tree and the incorrect assumption 
of instantaneous propagation of the pulse, which are important aspects of pulsatile 
haemodynamics.
18, 94-96
 A hybrid approach to reconcile different aspects of the wave 
26 
 
propagation and Windkessel models has been proposed by Tyberg and colleagues
97, 98
 but 
more experimental and/or epidemiological data will be required to validate this hybrid 
model.
99-101
 Nevertheless it has introduced a different interpretation of pulsatile 
haemodynamics e.g. AIx, traditionally ascribed to being the proportion of the pressure pulse 
contributed by pressure wave reflection, could instead be viewed as a function of the arterial 
Windkessel.
62
 The specific drug target for reducing excess pulastility could therefore 
potentially be one that can restore optimal timing and amplitude of pressure wave reflection 
and/or optimise arterial Windkessel function. 
 
1.8 Selective reduction of cPP 
Vasodilators are the most widely used treatment for hypertension and heart failure. In 
hypertension they have been shown to improve cardiovascular outcome due to their blood 
pressure lowering effects, although specific class effects beyond blood pressure lowering 
could also be implicated.
102
 Their common feature is their effect to reduce peripheral 
resistance
103-107
, once thought to be the sole haemodynamic culprit leading to hypertension. 
For the last two decades it has been increasingly recognised that brachial DBP control is 
often achievable but not SBP and PP, even under clinical trial conditions.
3, 8, 108
 Often 
multiple drugs are required to optimise SBP control
4, 109
 and in an attempt to optimise SBP, 
further resistance arteriolar vasodilatation precipitates a greater than desired fall in DBP thus 
potentially compromising perfusion pressure to vital organs. This is especially true in the 
context of ISH, the commonest type of hypertension in middle aged and elderly patients.
42
 
Beside reduction in peripheral resistance, therefore, the rationale for design of new 
vasodilators specifically targeting PP reduction should be the ability to manipulate arterial 





Figure 4: Schematic diagram showing the potential haemodynamic targets for optimisation of 
ventricular vascular coupling and pulse pressure reduction. 
 
Figure 4 shows the various components within the cardiovascular system that could 
potentially influence cPP. These include aortic stiffness, muscular arterial tone influencing 




Left ventricular contraction and relaxation 
Vascular tone in muscular conduit arteries 




Arterial stiffening is an ageing process driven by a complex interaction between systemic 
factors and local haemodynamic forces that activate mechanical and cellular changes within 
the arterial wall.
18, 110, 111
 Large elastic arteries are arbitrary defined as arteries with internal 
diameter above 2mm and muscular large arteries with internal diameter between 150μm – 
2mm.
22
 The structural integrity of the arterial wall, which is a balance of elasticity and tensile 
strength is determined by the proportion of elastin to collagen in the extracellular matrix and 
the number of vascular smooth muscle cells (VSMC).
110, 111
 From the aortic root down to the 
distal 5cm of thoracic aorta, elastin predominates over collagen and there are relatively few 
VSMC within the tunica media. However, beyond this the ratio reverses with more collagen 
compared to elastin and proportionally more VSMC; this phenomenon continues towards the 
distal muscular arteries.
22
  Arterial stiffening is not uniform: ageing and pathological 
processes stiffen proximal elastic large arteries more than distal muscular large arteries.
112-115
 
Since aortic stiffness has been shown to correlate with cPP in epidemiological studies
42, 71
, it 
is thought to be a potential therapeutic target for cPP. The positive correlation between aortic 
PWV, a functional measure of aortic stiffness and cPP is thought to be due to the early arrival 
of the BPW to the proximal aorta and/or an increase in Windkessel pressure. However, the 
relationship is likely to be more complex as vasodilators can alter cPP without affecting 
aortic PWV.
52, 63, 88, 116
  A further incentive in modifying aortic stiffness is that aortic PWV 
had been shown to be an independent predictor of cardiovascular outcome
117, 118
, thus it is a 
subject of much research interest.
44, 119
  
Arterial stiffening appears to be a result of interactions between genetic and 
environmental factors.
120-122
  A number of risk factors have been associated with aortic 
stiffening but age and blood pressure are the two most important factors in predicting the 
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progression of aortic stiffness.
123
 At the microscopic level, changes in the arterial wall occur 
mainly within the extracellular matrix and the cells it supports, especially VSMC and 
inflammatory cells. These changes are thought to occur in response to the autocrine, 
paracrine and neuroendocrine effects of excess salt and glucose and also to pulsatile stress.
22, 
110
 The roles of the renin-angiotensin system and of angiotensin II and aldosterone have been 
widely studied. Angiotensin II and aldosterone are thought to contribute to arterial stiffening 
by stimulating the signalling of multiple inflammatory pathways such as tissue growth factor-
β, NF-κB and reactive oxygen species production with reduction in nitric oxide (NO) 
bioavailability.
124-129
 The inflammatory effects upset the balance between the production of 
proteases and their inhibitors and also promote the synthesis of advanced glycation end-
products (AGE).  Matrix metalloproteinases (MMP) are proteases that are responsible for the 
accelerated breakdown of elastin and destruction of the molecular folding of collagen. AGE 
promotes the irreversible cross-linking of collagen, which together with overexpression of 
MMP, creates a stiff extracellular matrix. The inflammatory response also potentiates 
proliferation of VSMC and increased VSMC tone.
130-132
 Furthermore, it is thought that 
chronic cyclical stress from ageing leads to elastin fracturing and thinning, which is 
accelerated in the presence of hypertension.
18
 Since production of elastin is negligible in 




 Aortic stiffness can be altered directly through modification of arterial properties or 
indirectly through change in MAP.
134
 Duration of exposure to therapy may also be important 
as the effects on aortic stiffness may not be apparent in acute or short-term studies. A number 














 have shown reductions in PWV in human studies. Since, with the exception of 
statins these agents mostly reduce MAP, it is difficult to establish whether there is a MAP 
independent effect on arterial stiffness. The AGE breaker alagebrium is the only drug studied 
in humans so far that directly targets a molecular mechanism of arterial stiffness. Despite 




Selective large artery vasodilators 
The observations that cPP can be selectively lowered without alteration of aortic PWV 
suggest that there may be more than one mechanism to alter cPP.
52, 63, 88, 116
 Since cPP is the 
result of the interaction between left ventricular dynamics and aortic input impedance, 
vasodilators with an action on large arteries Windkessel or reservoir properties and/or 
pressure wave reflection could potentially alter cPP.
146, 147
 Furthermore the FPW generated by 
the left ventricles has been shown in epidemiological and mechanistic studies to influence 
cPP.
67, 148-150
 Therefore vasoactive substances with actions on left ventricular dynamics may 
also alter cPP.  
As discussed, vasodilators with selective actions on larger arteries could theoretically 
reduce cPP without overt effect on steady components of blood pressure.
151
 However, 
relatively little is known about whether the control of vasomotor tone in large arteries differs 
from resistance arterioles. Previous studies in rat aortas and mesenteric arteries suggested that 
nitric oxide (NO) has a greater influence on the vascular tone of large arteries and potassium 
channels in resistance arterioles.
152
 More recently in vivo human studies have suggested that 
both NO and potassium channels contribute to the resting vascular tone of muscular 
arteries.
153, 154
 However the effect of other vasoregulatory pathways that have a major 
influence on resistance arteriolar tone such as renin-angiotensin-aldosterone, prostaglandin 
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and endothelin systems on muscular conduit artery tone is unknown. The study of drug 
effects on large arteries became more refined when techniques of high resolution vascular 
ultrasound began to mature in the early 1980s. NO donors
147, 155
, Angiotensin receptor 
enzyme (ACE) inhibitors
156
, vasodilating β-blockers 157 and calcium channel blockers 49 have 
vasodilatory effects on large arteries. However, the relative effects of these drugs on tone in 
large and small arteries and whether any are relatively selective for large arteries is unknown. 
Of particular interest is the haemodynamic effect of low dose glyceryl trinitrate (GTN), 
which is remarkably effective in reducing cPP mainly through its action on pressure 
augmentation.
86, 116, 146
 In fact it has been shown that in middle aged subjects, administration 
of sublingual GTN 400 g reduced cPP by almost 30% with little effect on diastolic pressure 
and MAP.
71
 The mechanism of AP reduction is thought to be due to GTN’s unique selective 
action on large muscular arteries.
116, 146
 However its direct effects on ventricular dynamics, 
arterial reservoir and resistance arterioles could also be contributory.
86, 158-160
 It is speculated 
that GTN lacks effects on elastic arteries due to the relatively smaller proportion of VSMC 
within the wall of elastic arteries compared to large muscular arteries.
86, 88, 111
 The 
understanding of the vasoregulatory mechanism(s) controlling the tone of muscular large 
arteries could therefore be potentially important. 
Ventricular dynamics 
Because early studies in hypertension demonstrated cardiac output to be similar in 
hypertensive and normotensive subjects, it has been assumed that hypertension is a problem 
relating to the arterial tree. Thus diastolic hypertension is thought to result from an increase in 
peripheral arteriolar tone and hence in total peripheral resistance that leads to an elevation in 
MAP and DBP. Similarly an increase in PP is thought to result from increased arterial 
stiffness and/or pressure wave reflection. However, because SBP occurs early in systole when 
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only a relatively small proportion of the cardiac output has been ejected it is possible for 
cardiac output to remain unchanged but for the ventricular dynamics in early systole to 
influence the pressure pulse. Indeed, the water hammer equation described earlier means that 
in early systole, when there is no reflection, pressure will be determined by the product of 
aortic flow velocity (in turn determined by fibre shortening within the ventricle) and aortic 
PWV.  Thus ventricular dynamics may be an important determinant of the pulsatile 
components of blood pressure. 
 
1.9 Aims and hypothesis 
The central hypothesis of this thesis is that vasodilation of muscular conduit arteries will 
reduce pressure wave reflection and hence selectively reduce AP. 
Aims  
1a) To explore the regulation of vascular tone in muscular conduit arteries using vasodilators 
with known mechanisms of action and to establish drugs that are selective for muscular 
conduit arteries relative to resistance vessels. 
1b) To determine whether changes in PWV in muscular conduit arteries are determined by 
vascular tone.  
2) Determine whether reduction of AP by a drug selective for muscular conduit arteries is 
mediated by a reduction in pressure wave reflection. 




Local infusion of drugs into the brachial artery with measurement of their effects on the 
radial artery as an example of a conduit artery and resistance arterioles will be used to 
characterise the selectivity of drugs for muscular conduit arteries and resistance vessels. 
Haemodynamic effects of drugs that dilate conduit arteries will be examined using wave 
intensity analysis and by separating central pressure waveforms into forward and backward 
waves. Finally, wave separation analysis will be applied to hypertensive and normotensive 
subjects to determine the contribution of pressure wave reflection to pulsatility in 
hypertension. Drugs with relatively selective actions on the ventricle and arterial tree will be 
used to determine to what extent pulsatility may be influenced by ventricular dynamics 



































2.1 Brachial blood pressure measurements 
Brachial blood pressure was measured using the oscillometric method and according to 
established guidelines
161
 and manufacturer’s instructions (Omron 705CP, Omron, Japan or 
Intellivue MP30, Philips, Netherlands). At least 3 successive measurements were taken and 
averaged for the calibration of arterial tonometry measurements (see section 2.8) and for 
haemodynamic analysis. 
 
2.2 Venous occlusion plethysmography 
Human resistance arteriolar tone is difficult to measure directly in vivo. In research practice 
the measurement of forearm blood flow (FBF) by venous occlusion plethysmography is used 
to indirectly infer resistance arteriolar tone. When mean arterial pressure is stable, laminar 
fluid flow is proportional to the fourth power of vessel radius according to Hagen-Poiseuille’s 
law. 




Where Q = laminar flow, Pd = pressure difference, r = radius, µ = viscosity 
coefficient, l = length of vessel/tube. Therefore changes in resistance arteriolar tone can be 
inferred from changes in FBF.
162
 
The majority of FBF measured by venous occlusion plethysmography is believed to 
be arterial flow within the skeletal muscles.
162, 163
 By occluding venous return at a pressure in 
the upper arm that does not impede arterial inflow, forearm limb volume increases 
proportionally with blood flow.
164
 Change in forearm limb volume can be measured by 
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electrically calibrated mercury-in-silastic strain gauges, which have been shown to accurately 
reflect limb volume.
162, 163, 165, 166
  
Several conditions were standardised in order to ensure FBF measurements were 
accurate and reproducible. Studies were performed in a quiet, temperature-controlled room 
(24 to 26⁰C). Participants were studied at approximately the same time of day, after a 
standardised light meal and were asked to avoid caffeine and alcohol on the day of the study. 
The hand circulation, which has a  higher proportion of arterio-venous shunts compared to 
the forearm circulation, and hence more variable blood flow, was excluded by inflating wrist 
cuffs to a pressure above systolic blood pressure one minute before and during FBF 
measurements.
167
 Circumference of the widest part of the forearm was measured with an 
appropriate sized strain gauge (Hokanson, USA) 2-3cm shorter than the measured arm 
circumference, in accordance with the manufacturer’s instructions. Since the relationship 
between FBF and forearm volume is also dependent on the degree of distension within the 
venous system, the forearm was elevated above the level of the heart to ensure that the veins 
were not fully distended and measurements were made over after the first few seconds of 
upper arm cuff inflation, before the veins became fully distended.  
FBF measurement protocol 
Participants lay supine for at least 30 minutes before measurements were initiated. 
Brachial blood pressure was monitored non-invasively over the left arm throughout the study 
(Intellivue MP30, Philips, Netherlands).  The cuffs were applied to the upper arms and the 
wrists for venous occlusion and interruption of the hand circulation respectively. Strain 
gauges were applied to the widest part of the forearm as previously described. One minute 
before FBF measurements, wrist cuffs were inflated to 180mmHg to allow FBF to stabilize. 
FBF measurements were taken in both arms simultaneously by inflating the upper arm cuffs 
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at 40mmHg to achieve venous occlusion without interruption of arterial inflow. Five FBF 
measurements were taken with the upper arm cuffs inflated at 10 second intervals and with a 
5 second deflation period in between. Strain gauge voltage was recorded on an electronic 
chart recorder (Powerlab, AD instruments, Australia). FBF was calculated from the initial 
slope of the strain gauge vs time plot over the initial period of upper cuff occlusion when 




2.3  Radial artery diameter measurements 
Simultaneous assessment of radial artery diameter and FBF during brachial artery infusion of 
vasoactive substances provides a powerful tool to probe the differential vasoregulatory 
pathways of muscular conduit arteries and resistance arterioles. High resolution vascular 
ultrasound measurements of the radial artery diameter were obtained during steady state 
conditions within a few minutes of FBF measurements. In order to avoid a possible influence 
of a reactive hyperaemic response following deflation of wrist cuff, radial artery diameter 
measurements were performed before each set of FBF measurements. A 10MHz ultrasound 
probe (Aspen, Siemens, Germany) was placed 3 to 5cm distal to the point of arterial 
cannulation to image the right radial artery. Once a good quality two dimensional radial 
artery image was acquired, the ultrasound probe was placed in a stereotactic holder with 
micrometer adjustment to allow precise optimisation of image quality throughout the study. 
End-diastolic (ECG referenced) radial artery diameter (RAD) was obtained from images 
acquired every 3 seconds over 2 minutes at baseline and when steady state had been achieved 
during drug infusion.  Images were analysed off-line using automated software (Brachial 
analyser, Medical Imaging Applications, USA) which provided a mean diameter over a 
length of artery of approximately 10mm. The coefficient of variation of arterial diameter 
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measurements repeated at baseline and during drug infusion was 4%. The change in radial 
artery diameter was reported as percentage change relative to baseline. 
 
2.4 Pulse wave velocity measurements of the brachial-radial artery 
Pulse wave velocity (PWV) measurements over the brachial-radial arteries were carried out 
to investigate the relationship between arterial tone and stiffness of muscular large arteries. 
PWV was measured over the brachial to radial path from simultaneous pressure cuff 
recordings at each site using the Vicorder ® system (Skidmore Medical, UK). The Vicorder® 
device uses a modified cross-correlation algorithm for measuring transit times with a 
resolution of 1.8 milliseconds and the coefficient of variation of readings repeated during the 
course of one study was 3%. The path distance was determined using a measuring tape taken 
from the proximal edge of the upper arm cuff to that of the wrist cuff.  Three measurements 
were made following radial artery diameter and FBF measurements and the average PWV 
was reported. Data was considered acceptable when at least five sequential good quality 
waveforms were obtained from each cuff. 
 
2.5 Intra-brachial artery drug infusion 
Vasoactive drugs were infused directly into the right brachial artery to probe the regulatory 
mechanisms of vascular tone in muscular conduit and resistance arteries in the human 
forearm. When infused locally, physiological or pharmacological concentrations can be 
achieved in the forearm circulation with negligible systemic drug delivery. This route of drug 
administration, therefore, avoids a systemic haemodynamic response and consequent 
activation of baroreceptors and other autonomic responses, which would make interpretation 
of the local vasodilatory responses difficult. A 27 gauge unmounted steel needle (Cooper’s 
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Needle Works, UK) sealed with dental wax to an epidural catheter (Smiths Medical Portex ®, 
UK) was inserted into the right brachial artery using ≤1ml of 1% lidocaine hydrochloride 
(Braun Pharmaceuticals) to provide local anaesthesia. Following successful cannulation, 
either 0.9% saline or drugs dissolved in 0.9% saline vehicle were infused at 1ml/min using a 
syringe driver (Injectomat, Agilia®, Fresenius Kabi, Germany). Cumulative doses of 
comparator drugs were infused at each dose until steady state was achieved (typically 
between 6-12 minutes). Infusion of each drug was preceded by a baseline period, a washout 
period or studies were performed on different occasions. Brachial cuff blood pressure 
measurements and FBF were obtained from the non-cannulated arm to ensure there were no 
significant systemic responses that would influence the interpretation of the results of the 
FBF response to local infusion of the drugs. 
 
2.6 Invasive aortic pressure and flow velocity measurements 
Invasive aortic blood pressure and flow velocity measurements were carried out by Dr Brian 
Clapp during cardiac catheterisation at St Thomas’ Hospital cardiothoracic unit in patients 
undergoing clinically indicated angiography and/or angioplasty for the 
investigation/treatment of coronary artery disease.  Following routine preparations for 
angiography, vascular access to the right femoral or radial artery was established with a 6Fr 
haemostatic sheath. A 6Fr-guiding catheter (JL4, Boston Scientific, UK) was advanced to the 
aortic root over an 0.35” wire using standard techniques and connected to a closed flushing 
system with a haemostatic valve. All subjects were systemically heparinized with 
unfractionated heparin (Wockhardt, UK) to reduce the risk of thrombus formation within the 
catheter.  A Combowire pressure and Doppler flow velocity transducer (9500XT, 
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VolcanoCorp, USA) was passed through the guiding catheter and the tip of the wire was 
positioned under fluoroscopic guidance in the proximal aortic root to obtain optimal coaxial 
stable pressure and flow tracings. The transducer was connected to a monitor (Combomap, 
VolcanoCorp, USA) with an analogue output at a frequency of 1 kHz and the signals were 
recorded via an analogue to digital converter (Micro 1401, Cambridge electronic design, 
UK).  Aortic root pressure and Doppler flow velocity were obtained over at least 10 cardiac 
cycles at baseline and following administration of drugs (see below). All measurements were 
taken before the administration of ionic contrast agents for the subsequent angiogram or 
angioplasty except for a subset of subjects receiving intra-coronary drug infusions where 
diagnostic coronary angiography was performed before the research study to ensure the 
absence of significant left main stem or critical left anterior descending coronary artery 
disease that could affect the distribution of drug within the left ventricle. The aortic Doppler 
flow velocity waveforms were integrated over time and multiplied by aortic cross-sectional 
area (estimated from body surface area) to obtain a measure of stroke volume and hence 
cardiac output and total systemic vascular resistance. 
 
2.7 Non-invasive carotid pressure measurements 
Since, invasive measurements of aortic pressure can only be obtained at the time of cardiac 
catheterisation, non-invasive measures of carotid pressure were used as a surrogate for aortic 
pressure in subjects for whom cardiac catheterisation was not clinically indicated. Although 
the carotid and aortic pressure waveforms are not identical they resemble each other closely 
both at rest and during dynamic testing with physiological manoeuvres and drugs.
168
 Correct 
calibration of the carotid pulse is important due to pulse pressure amplification and the most 
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widely used method is to calibrate carotid pressure from brachial mean and diastolic blood 
pressure on the assumption of equality of these pressures at central and peripheral sites.
20
 
Apart from the same variation in waveform morphology other drawbacks of using the carotid 
pulse as a surrogate for the aortic pulse include the difficulty in obtaining a stable pressure 
tracing with applanation tonometry, the potential activation of baroreceptors and theoretical 
adverse effects on undiagnosed carotid plaques. However, the carotid pressure waveform has 
been widely used as a surrogate for the aortic pressure pulse in epidemiological studies, 
clinical trials and mechanistic haemodynamic studies.
24, 54, 60, 169-171
 
Measurements were performed in a quiet temperature controlled (24-26 ⁰C) room. 
Subjects were asked to avoid caffeine and alcohol on the day of the study. All pressure 
measurements were taken supine following 20-30 minutes resting. Radial and carotid 
pressure waveforms were obtained by applanation tonometry using the SphygmoCor system 
(AtCor, Australia). Approximately 10 cardiac cycles were obtained and ensemble averaged. 
Waveforms that did not meet the in-built quality control criteria in the SphygmoCor system 
were rejected. Brachial blood pressure was measured in triplicate by a validated oscillometric 
method (Omron 705CP, Omron Health Care, Japan) and used to calibrate radial waveforms 
to obtain MAP. Carotid waveforms were calibrated from MAP and diastolic brachial blood 
pressure on the assumption of equality of these pressures at central and peripheral sites. 
Carotid pressure and aortic Doppler flow velocity (see below) were measured under the same 






2.8 Non-invasive aortic flow measurements 
Ultrasound imaging was performed by Dr Benyu Jiang using the Vivid-7 ultrasound platform 
(General Electric Healthcare, UK). Flow velocity across the aortic valve was recorded using 
continuous wave Doppler obtained from an apical 5- chamber view. Stroke volume (SV) was 
calculated from the product of VTI and cross-sectional area of the aortic valve (obtained in 
the parasternal long axis view). All measurements were averaged over at least 3 cardiac 
cycles.  Cardiac output (CO) was calculated from SV and heart rate and total peripheral 
resistance (TPR) from mean arterial pressure (MAP) divided by CO.  
 
2.9 Waveform Post-processing 
Aortic Doppler flow velocity and aortic/ carotid pressure waveforms were stored and 
analysed in Matlab (2012b, Mathworks, USA) for wave intensity, wave decomposition and 
pulse wave analyses. The first systolic shoulder of the aortic/carotid pressure waveform was 
identified as the first local minimum of the first derivative of the pressure curve (and 
confirmed by visual inspection) to determine P1, P2 and AP, the difference between P2 and 




Figure 5: Aortic pressure and flow velocity waveforms and the components of central pulse 
pressure. P1 is the first shoulder of the waveform above diastolic pressure and AP is the 
difference between P2 and P1. 
Pressure wave decomposition into forward and backward waves was performed using 
the equations derived by Euler in 1775, based on the conservation of mass and momentum. 
The aorta was considered as an elastic tube, blood as an incompressible and inviscid fluid and 
the flow was assumed to be unidimentional. These equations were solved using the method of 
Parker 
172





























Where P and U are the pressure and the flow velocity respectively, T is the foot to foot 
duration of a pulse, ρ is the density of blood and c the speed of travel of waves equal to the 
local pulse wave velocity (PWV). The wave speed c was calculated using the single point 
method described by Davies et al using the following formula.
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Where P and U are the pressure and flow velocity respectively. This method of wave 
separation produces the same results as that performed in the frequency domain.
174
 
Separation of the pressure wave allows the individual contributions of the FPW and BPW to 
each of the components (e.g. P1, P2 and AP) of the pressure pulse to be determined. Since the 
BPW is usually regarded as the result of “reflection” of the FPW. The ratio between the peak 
amplitude of FPW: BPW is often used to obtain a reflection coefficient. This allowed the 
contribution of the forward wave and reflected wave to AP to be assessed and hence to allow 




Figure 6: Aortic pressure waveform decomposed into forward and backward pressure 
components. 
Wave intensity analysis of aortic pressure 











Where P and U are the pressure and the flow velocity respectively. With wave 
intensity analysis pressure waves can be further categorized as compression or expansion 
(suction). Thus wave separation and intensity analysis allow waves to be characterised 
according to their origin (either from the ventricle for a FPW or from the peripheral 
circulation for a BPW) and whether that are generated by compression or suction at the point 
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of origin.  Thus a forward compression wave (FCW) is thought to be generated by the force 
of contraction of the left ventricle and a forward expansion wave (FEW) in early systole by 
the braking effect of the ventricle as it starts to relax. A backward compression wave can be 
generated by reflections of the FPW wave from the peripheral arterial tree. Other minor 





Figure 7: Wave intensity analysis of an aortic pressure waveform in systole. FCW, forward 
compression wave; FEW, forward expansion wave; FEWls, late systolic forward expansion 
wave; BEW, backward expansion wave; BCW, backward compression wave; BCWls, late 




Statistical analysis was performed using SPSS version 19. Subject characteristics were 
summarised as means ± SD. Unless where stated results are expressed as means ± SE. 
Comparison between groups of subjects or response to different drugs was performed using 
Student’s paired t-test or by analysis of variance for repeated measures. In the cases of non-
normally distributed data, a Wilcoxon signed-rank test was used. All tests were 2-tailed and 
P<0.05 was considered significant. The within subject coefficient of variation was used to 
assess reproducibility where appropriate and calculated by dividing within subject standard 
























REGULATION OF VASCULAR TONE AND PULSE 
WAVE VELOCITY IN HUMAN MUSCULAR 
CONDUIT ARTERIES: SELECTIVE EFFECTS OF 
NITRIC OXIDE DONORS TO DILATE MUSCULAR 





Human pharmacology of vasodilator drugs has focused almost exclusively on their actions on 
vascular smooth muscle in “resistance” vessels comprising the arterioles and microvessels 
less than 100 µm in diameter that determine peripheral vascular resistance and hence mean 
arterial blood pressure (MAP).  The pulsatile component of blood pressure, which is of more 
prognostic importance than MAP, especially in older subjects
175
 is, however, dependent on 
characteristics of large elastic and muscular conduit arteries.
176, 177
 Vasodilator drugs have 
little effect on large elastic arteries (other than the passive effect due to a change in blood 
pressure) presumably because these have little smooth muscle.
178
 By contrast, conduit arteries 
are comprised mainly of vascular smooth muscle and, dependent on basal vascular tone, 
might be expected to be responsive to vasodilators. Conduit arteries influence the pulsatile 
component of blood pressure through their contribution to total arterial functional compliance 
or reservoir property and to pressure wave reflections.
179
  Pressure wave reflections may be 
important over and above their contribution to blood pressure, since they are predictive of 
cardiovascular mortality independently of conventional blood pressure components.
47
 The 
effects of wave reflections may be influenced both by artery diameter and local arterial pulse 
wave velocity within conduit arteries (PWV), since this PWV influences the timing and 
functional consequence of reflections in terms of ventricular loading.
179
  
  The aim of the present study was to firstly compare the effects of different classes of 
vasodilator drug on arterial tone and vasodilation of the radial artery, as an example of a 
muscular conduit artery, and on forearm resistance vessels representative of those 
contributing to total peripheral vascular resistance. A second objective was to examine the 
relationship of local PWV within the radial artery to vascular tone and diameter. By infusing 
drugs locally into the brachial artery I was able to study these effects independent of any 
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change in blood pressure or activation of neurohormonal reflexes.  I examined drugs acting 
through the cyclic guanosine monophosphate (cGMP) pathway: the NO donors nitroglycerin 
and nitroprusside acting on soluble guanylyl cyclase (sGC) and brain natriuretic peptide 
(BNP)  acting on particulate guanylyl cyclise (pGC) as there is indirect evidence that these 
may exhibit relative specificity for muscular arteries.
180
 I compared these cGMP agents to the 
alpha-adrenergic antagonist phentolamine that would oppose sympathetically induced tone, 
the calcium channel antagonist verapamil that may antagonise myogenic tone and 




Participants were normotensive healthy men aged 19 – 53 years (mean±SD, 27.6±8.4 years). 
All were asymptomatic with no history of or risk factors for cardiovascular disease (mean 
serum total cholesterol, 4.3±1.1 mmol/L and blood pressure 126±10/ 73±9 mmHg) and were 
on no regular medication. Due to the large number of drugs examined and constraints on the 
duration of each intra-arterial study and number of arterial cannulations performed on each 
subject not all drugs could be administered to all subjects. However, as far as possible, the 
allocation of study drug to subjects was randomised to avoid bias. Forty subjects were studied 
in total with effects of each drug being studied in a minimum of 8 subjects (except as noted 
below for norepinephrine where n=7) and an average number of 2 drugs studied per subject. 
There were no significant differences in subject characteristics (age, blood pressure or serum 
lipids) between subjects receiving the various drugs. The study was approved by the London 
Westminster Research Ethics Committee, and written informed consent was obtained from all 
participants.   
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Study 1: Effects of vasodilators on muscular conduit arteries and resistant arteries 
Studies were performed in a quiet temperature-controlled room (24-26°C). Subjects were 
studied at approximately the same time of day, after a standardised light meal and were asked 
to avoid caffeine and alcohol on the day of the study. Subjects lay supine for at least 30 
minutes before measurements were initiated. Brachial blood pressure was monitored non-
invasively over the left arm throughout the study (Intellivue MP30, Philips, Netherlands).  A 
27 gauge unmounted steel needle (Cooper’s Needle Works, UK) sealed with dental wax to an 
epidural catheter (Smiths Medical Portex ®, UK) was inserted into the right brachial artery 
using less than 1ml of 1% lidocaine hydrochloride (Braun Pharmaceuticals) to provide local 
anaesthesia. Either 0.9% saline or drugs dissolved in 0.9% saline vehicle were infused at 
1ml/min using a syringe driver (Injectomat, Agilia®, Fresenius Kabi, Germany). Cumulative 
doses of comparator drugs: nitroprusside (NP, 0.3, 1, 3 µg/min, n=11); nitroglycerin (NTG. 
0.03, 0.1, 0.3, 1 µg/min, n=8); nesiritide (BNP, 0.1, 0.3, 1, 3 µg/min, n=8); phentolamine 
(PHT, 10, 30, 100 µg/min, n=9);  verapamil (VER, 10, 30, 60 µg/min, n=8); hydralazine 
(HYD, 10, 30, 100 µg/min, n=8) were infused for 12 min (at each dose). With the exception 
of NP (the infusion of which was followed by a washout period and then infusion of a second 
drug), the duration of action of drugs was too long to allow for more than one drug to be 
infused on one visit and therefore each drug was given on separate occasions.  
 
Acquisition of radial artery diameter (RAD) and forearm blood flow measurements 
were carried out as described in Chapter 2. End-diastolic (ECG referenced) radial artery 
diameter (RAD) was obtained from images acquired every 3 seconds over 2 minutes and after 
7 minutes infusion when steady state had been achieved (before measurement of forearm 
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blood flow as described below in order to prevent cuff inflation from interfering with 
ultrasound images).   
Following acquisition of ultrasound images, forearm blood flow (FBF) measurements 
were taken in both arms simultaneously by venous occlusion strain gauge plethysmography 
(Hokanson, USA) during the final 9-12 min of drug infusion. Wrist cuffs were inflated to 
180mmHg. Upper-arm cuffs were inflated to 40mmHg intermittently and five measurements 
used to calculate mean FBF.  
 
Study 2: Relationship between pulse wave velocity and muscular conduit artery diameter  
In this study the aim was to examine the relation between RAD and PWV irrespective of 
FBF. To modulate arterial tone over a wider range, I used norepinephrine (NE, 0.01, 0.02, 
0.04 µg/ min, n=7) infused into the brachial artery alone and co-infused with PHT to generate 
beta-adrenergic mediated vasodilation (beta-adrenergic vasodilation being opposed by alpha-
adrenergic mediated vasoconstriction). NTG (0.03, 0.1, 0.3, 1µg/min, n=8) was used to 
generate an increase in RAD.   PWV was measured as described in Chapter 2 using the 
Vicorder ® system (Skidmore Medical, UK). The path distance was taken from the proximal 
edge of the upper arm cuff to that of the wrist cuff. RAD and PWV were measured at 
baseline and after 8 min of infusion of each dose of drug.   
 
Characteristic impedance of the forearm vascular bed (Zc) was calculated from PWV 








derived from the water hammer equation,
181
 where 𝜌 is blood density. Changes in PWV were 
partitioned into those due to a change in the intrinsic elasticity of the arterial wall as 
represented by Young’s incremental elastic modulus (Einc), thickness of the arterial wall (h) 







Drugs were obtained from Baxter Healthcare (saline); Hospira Incorporation (NP and NTG); 
Alliance pharmaceuticals (PHT); Sovereign Medical (HYD); Abbott laboratories (VER); 
Scios Incorporation (BNP/Nesiritide) and Aguettant Ltd (NE). 
 
Statistical analysis 
Results are summarised as means±SEM. In order to compare effects of drugs on RAD for the 
same degree of action on resistance vessels, dose response curves were extrapolated, for each 
subject, to obtain a RAD representative of fixed absolute increments in FBF of 1, 2 and 3 
ml/min/100ml. Differences between means were evaluated for statistical significance by 
analysis of variance ANOVA (for repeated measures whereas appropriate). SPSS version 16 




Local intra-arterial infusion of the vasodilator drugs produced a dose-dependent increase in 
FBF in the infused arm with an approximate 2-3 fold increase in FBF at the highest dose 
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(table 1).  There were minor or non-significant changes in FBF in the non-infused control arm 
(table 1) indicating that local effects in the infused arm were unlikely to be influenced by 



















Table 1 Forearm blood flow (FBF) in infused and non-infused arms (con) and radial 
artery diameter (RAD) in infused arm during brachial artery infusion of vasodilator 
drugs 
 








Phentolamine (n= 9) 
Vehicle 3.56±0.43 1.91±0.18 2.52±0.08 
10 µg/min 5.21±0.39† 2.34±0.26 2.59±0.07 
30 µg/min 6.26±0.58† 2.16±0.28 2.60±0.06 
100 µg/min 6.91±0.57† 2.21±0.2 2.61±0.07 
 
Verapamil (n= 8) 
 
Vehicle 2.66±0.35† 2.56±0.28 2.64±0.21 
10 µg/min 5.23±0.58† 2.60±0.25 2.81±0.22† 
30 µg/min 7.65±1.01† 2.83±0.32 2.80±0.22 
60 µg/min 9.46±1.01† 3.3±0.43† 2.88±0.23* 
 
 BNP (n= 8) 
 
Vehicle 3.29±0.50 3.33± 0.58 2.49±0.11 
0.1 µg/min 3.53±0.70 2.83±0.15 2.60±0.10 
0.3 µg/min 4.39±0.57* 2.73±0.15 2.69±0.10* 
1 µg/min 6.26±0.86† 2.78±0.3 2.75±0.10* 
3 µg/min 7.56±1.00† 2.56±0.15 2.81±0.11* 
 
Hydralazine (n= 8) 
 
Vehicle 3.42±0.61 2.21±0.25 2.33±0.14 
10 µg/min 4.72±0.62† 2.26±0.28 2.48±0.16* 
30 µg/min 7.39±0.87† 2.46±0.33 2.64±0.17† 
100 µg/min 13.2±1.66† 3.26±0.56* 2.76±0.19‡ 
 
Nitroprusside (n= 11) 
 
Vehicle 3.25±0.24 2.74±0.37 2.41±0.11 
0.3 µg/min 5.22±0.46† 2.56±0.2 2.78±0.10 
1 µg/min 7.30±1.00† 2.89±0.29 2.89±0.10* 
3 µg/min 9.31±1.05† 2.78±0.31 2.96±0.11† 
 
Nitroglycerin (n= 8) 
 
Vehicle 3.10±0.37 2.84±0.44 2.59±0.07 
0.03 µg/min 3.66±0.45* 2.43±0.29 2.95±0.67† 
0.1 µg/min 4.38±0.48* 2.48±0.43 3.11±0.09† 
0.3 µg/min 4.50±0.43† 1.94±2.41 3.22±0.09‡ 
1 µg/min 6.29±0.55‡ 2.5±0.27 3.28±0.09‡ 
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With the exception of PHT, all vasodilators produced a significant increase in RAD in 
the infused arm. However, effects on RAD differed between the drugs. This was more 
marked when effects on RAD were compared for a given increase in FBF (figure 1). PHT, 
VER and BNP produced relatively little dilation (mean dilation < 9%).  NTG and to a lesser 
extent NP produced greater dilation (figure 1, P<0.01 and P<0.05 compared to PHT).  For the 
lowest increase in FBF of 1 ml/min/100 ml, dilation was 1.5±1.0, 7.8±1.6 and 15.8±3.2% for 
PHT, SNP and NTG respectively (P<0.01 for NTG vs. PHT) and at the highest increase in 
FBF of 3 ml/min/100ml, 3.4±1.4, 16.8±2.6 and 26.0±3.5% for PHT, NP NTG respectively 
(P<0.0001 for NTG vs. PHT and P<0.001 for NP vs. PHT).  HYD produced an intermediate 
degree of dilation and the order of efficacy to dilate the radial artery was: 
NTG>NP>HYD>BNP>VER>PHT, irrespective of the increase in FBF at which actions on 








Increase in radial artery diameter compared at doses of drugs that produce the same increase 
in forearm blood flow (FBF). ** P<0.01 compared to phentolamine, verapamil and BNP. 
*P<0.05 compared to phentolamine. Bars represent mean values; error bars are SEM, n=9, 8, 




NE (0.04µg/min) reduced RAD by 11.4±4.1% but when co-infused with PHT (100 µg/min) 
increased RAD by 5.8±3.5%. NTG (1g/min) increased RAD by 32.1±5.4%. Over this range 
of modulation of vasodilator tone, changes in PWV and Zc were closely related to those in 
RAD. Changes in RAD of 20% equated to changes in PWV and Zc of ~5% and ~-50% 













a) Relation between changes in radial artery pulse wave velocity (PWV) and diameter 
during modulation of arterial tone with nitroglycerin (NTG, n=8), phentolamine (PHT, 
n=8), norepinephrine (NE, n=7) alone and with PHT (n=7). Each symbol represents mean 
values for each dose of drug. The solid line is the line of best fit by linear regression; 
Pearson correlation coefficient, R=-0.89, P<0.05. 
b) Relation between change in local characteristic impedance (Zc) and radial artery diameter 
during modulation of arterial tone as in (a). R= -0.99, P<0.001. 
 
3.4 Discussion 
To my knowledge, this is the first study to systematically examine the effects of different 
classes of vasodilator drugs on both muscular arteries and resistance vessels.  For the same 
degree of forearm resistance vessel dilation, the vasodilator drugs studied differed widely in 
their effects on RAD. The NO-donors NTG and NP acting through sGC had marked 
vasodilator effects on the muscular artery with NTG significantly more effective than NP. 
NTG produced a > 20% increase in RAD. The functional consequences of such an increase in 
diameter result from the change in local Zc influencing the local dynamic pressure/flow 
relation with greater initial flow and hence shear stress for a given pressure and a reduction in 
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in RAD will produce an approximate 
50% reduction in Zc. By contrast to NTG and NP, BNP, acting through pGC rather than sGC, 
had less effect than either NTG or NP. Differential effects of the NO-donors could relate to 
variation in the NO species released (e.g. different redox states and/or thiol intermediates) 
with potential actions on potassium channels and mechanism other than cGMP. Differences 
between the sGC and pGC activators could be due to spatial compartmentalisation of cGMP 
production - whereby a higher concentration of cGMP accumulates close to the sarcolemma 
when activated by sGC in the cytosol as opposed to membrane bound isoform pGC.
182, 183
  
The marked vasodilator effects of NTG demonstrate that there is considerable resting 
tone within muscular arteries. This could be sympathetically mediated (as in resistance 
vessels), due to an intrinsic “myogenic” response (not necessarily causing vasoconstriction in 
response to an increase in transmural pressure but an increase in tone) or another mechanism. 
Despite producing similar effects on resistance vasculature to NTG and reversing constriction 
produced by the alpha-adrenergic agonist NE, the alpha-adrenergic antagonist PHT had 
relatively little effect on muscular artery diameter. This suggests there is little 
sympathetically mediated resting tone within these muscular arteries. The myogenic response 
is thought to be mediated in part through calcium channels and, in some vessels, is inhibited 
by the L-type calcium channel blocker VER.
184
  In the present study, however, I found that 
whilst VER dilated resistance vessels with similar efficacy to PHT, it had only minor effects 
on the muscular artery. Thus if a myogenic response is implicated in resting tone within 
muscular arteries it is likely that this is mediated through a mechanism other than L-type 
calcium channels but which is functionally or directly antagonised by an NO donor. In this 
regard it is notable that NO-donors reduce myogenic tone in rat arteries by a mechanism 





A second objective of my study was to examine the relationship between arterial 
vasodilator tone and local PWV in the radial artery. Previous studies have demonstrated that 
PWV is influenced by NO, with PWV increased or reduced by inhibition or stimulation of 
NO synthase respectively
186
 and decreased by administration of an exogenous NO donor.
187
 
However, it is unlikely that these findings relate to a specific effect of NO on arterial 
elasticity and PWV may simply relate to arterial smooth muscle tone irrespective of the 
signalling pathway through which this is modulated. In the present study I altered arterial 
vasodilator tone over a wide range, using NE to constrict the artery, PHT to antagonise the 
actions of NE on alpha-adrenergic receptors and thus dilate the artery through its unopposed 
vasodilator actions on beta-adrenergic receptors and NTG as an NO donor and dilator. 
Changes in PWV were closely related to those in arterial diameter, irrespective of the 
vasoactive drug used to modulate arterial tone. This suggests that, under physiological 
conditions, PWV in muscular arteries is determined by smooth muscle tone rather than being 
influenced by a specific signalling pathway. Since PWV is known to be dependent on 
transmural pressure,
187
 this finding is consistent with arterial tone in muscular arteries being 
generated mainly as an intrinsic ‘myogenic’ response to transmural pressure.   Although a 
measure of ‘arterial stiffness’, PWV may be influenced both by arterial diameter and the 
intrinsic elasticity of the arterial wall. The Moens-Korteweg equation allows change in PWV 
to be partitioned into that due to the change in Einc.h and RAD, with the percentage change 
in PWV predicted to be 50% of that arising from change in RAD if Einc.h remains constant.  
Figure 2 shows that the percentage change in PWV was ~25% of that in RAD suggesting that 
Einc.h  increases. Since an increase in RAD necessarily implies a reduction in h as the wall is 
stretched, my results suggest a paradoxical increase in Einc. This behaviour exemplifies the 





The clinical relevance of my findings relates to the potential to selectively reduce tone 
of muscular arteries, with the resultant vasodilatation and decrease in PWV reducing pressure 
wave reflection and delaying the time of its arrival in systole; actions that will reduce systolic 
blood pressure and pulse pressure.
86
 Selective vasodilatation of muscular as opposed to 
resistance vessels means that diastolic pressure will be relatively unaffected. Such 
haemodynamic effects are likely to be of particular benefit in subjects with isolated systolic 
hypertension in whom myocardial wall stress and oxygen consumption are elevated due to 
raised systolic pressure but in whom a reduction of diastolic pressure in parallel with systolic 
pressure may compromise myocardial perfusion during diastole.
189
 It is notable that NTG is 
remarkably effective at reducing systolic pressure (particularly central systolic pressure
19
) 
with little effect on diastolic pressure.
63, 190, 191
 The present results suggest that, of currently 
available vasodilator agents, NO donors show the greatest selectivity for muscular arteries. 
Furthermore the heterogeneity between NO donors suggests that this is dependent on the 
exact NO-signalling pathway and that there may be potential to exploit this to enhance the 
selectivity of these agents to dilate muscular arteries. In this regard it is notable that the NO 
donor sinitrodil can increase compliance of the brachial artery without effects on systemic 
vascular resistance.
147
  It should be noted that the present study provides insight into local 
regulation of arterial tone and PWV in muscular arteries in the absence of changes in 
systemic haemodynamics or neurohormonal activation. Such changes, such as a reduction in 
mean arterial pressure, for example, may result in a secondary reduction in arterial diameter. 
There is, therefore, no substitute for systemic studies to assess overall haemodynamic effects 






Whilst the regulation of vascular tone in resistance vasculature has been studied extensively, 
relatively little is known regarding that in muscular conduit arteries. Such tone in muscular 
arteries is likely to be important since it influences systemic haemodynamics through effects 
on the functional compliance of the arterial tree and on pressure wave reflection. The present 
study suggests that, under resting conditions, the tone of muscular arteries is largely 
independent of sympathetic outflow acting on alpha-adrenergic receptors but is generated as a 
myogenic response to transmural pressure. NO donors appear highly effective at antagonising 
such resting tone with greater action on muscular arteries relative to resistance vessels than 
calcium-channel antagonists. However, there is considerable heterogeneity between drugs 
acting through the NO-cGMP pathway in their selectivity for muscular arteries. This suggests 
that there is the potential to design drugs acting through this pathway which dilate muscular 
arteries but have minimal effects on resistance vasculature and which would be useful in 
treating systolic hypertension. 
In conclusion, the smooth muscle tone of conduit arteries that determines arterial 
diameter and PWV is likely to generated by an intrinsic myogenic response to transmural 
pressure and, for an equivalent action on resistance vessels, is functionally or directly 















AUGMENTATION PRESSURE IS INFLUENCED 
BY VENTRICULAR CONTRACTILITY/ 
RELAXATION DYNAMICS: NOVEL MECHANISM 













Aortic or central pulse pressure (cPP) determines the pulsatile load on the left ventricle, 
coronary and carotid arteries and is a major risk factor for adverse cardiovascular events, with 
at least as strong a relation to such events as peripheral pulse pressure.
47, 51, 192
 cPP is widely 
assumed to be determined by the interaction of an outgoing forward pressure wave (FPW) 
generated by ventricular contraction and a backward going pressure wave (BPW) due to 
reflections from the periphery of the circulation.
18, 193
 These components of cPP are separated 
by the first systolic shoulder of the aortic pulse (figure 10). The height of this above diastolic 
blood pressure (P1) is attributed to the FPW and the height above P1, the augmentation 
pressure (AP), to the BPW.
194
 Augmentation index (AIx), the ratio of AP to cPP is widely 
used as a measure of “pressure wave reflection”. This interpretation has, however, been 
criticised because of the poor relationship between the magnitude and timing of reflected 
waves with respect to AP.
60, 61
 Nitroglycerin (NTG) has a particularly marked action to 
reduce AP and hence cPP attributed to a reduction in timing or amplitude of pressure wave 
reflections
19, 86, 146
  However, an alternative explanation relates to an influence of 
nitrovasodilation on contraction-relaxation dynamics of the myocardium, effects observed in 
isolated myocytes and in vivo.
158, 159
  
The aim of the present study was to determine the mechanism by which AP is 
selectively reduced by nitroglycerin (NTG). I made simultaneous measurements of aortic 
pressure and flow and used wave intensity analysis to separate pressure waves into FPW and 
BPW components.
172
 Pressure waves were further categorized as compression or expansion 
(suction). A primary forward compression wave (FCW) arises from the “push” of the 
ventricle against the arterial tree and a systolic backward compression wave (BCW) from the 
push of the arterial tree against the ventricle. A late systolic forward expansion wave (FEW) 
66 
 
arises from the braking effect of the ventricle in late systole.
195
 These measurements together 
with cardiac output and the impedance of the arterial tree were obtained at baseline and after 
systemic administration of NTG.  To further distinguish between effects of NTG related to an 
action on the myocardium and arterial tree, I examined effects of intracoronary infusion of 
NTG at a dose below the threshold required to produce systemic effects.   
 
Figure 10 
Central aortic pressure and flow waveforms showing components of central pulse pressure 
(cPP), height above diastolic pressure of  the first shoulder of the aortic pressure waveform 
(P1) and augmentation pressure (AP). 
 
4.2 Methods 
Subjects (n=30, 11 women, mean ± SD age 61±13 years) were recruited from those attending 
Guy’s and St Thomas’ cardiothoracic unit for diagnostic angiography or elective 
percutaneous coronary angioplasty. Subjects with acute coronary syndromes, those with 
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significant valvular disease, heart failure of severity greater than NYHA grade 2 and rhythm 
other than sinus rhythm were excluded. Subject characteristics including medication are 
shown in table 2. 
Table 2 Subject characteristics 
Characteristic Study 1 (n = 20) Study 2 (n = 10) 
Age (years) 63±11 57±17 
Sex  (men/women) 10/10 9/1 
Diabetes mellitus (%)  30 40 
Aortic systolic blood pressure (mmHg) 136±23 139±39 
Baseline diastolic blood pressure (mmHg) 73±13 69±8.3 
Body mass index (kg/m
2
) 28±8.6 28±3.1 
Total cholesterol (mmol/L) 4.5±1.2 5.0±0.2 
High density lipoprotein (mmol/L) 1.2±0.5 1.0±0.3 
Drug treatment   
ACEI/ARB  (%) 45 70 
β-blocker use (%) 45 40 





 ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, 
calcium channel blocker. 
 
Study 1 Central haemodynamics and response to systemic nitroglycerin 
Invasive blood pressure and flow measurements were carried out as described in chapter 2. 
Baseline measurements of aortic root pressure and Doppler flow velocity were obtained over 
at least 10 cardiac cycles. Repeat aortic pressure and Doppler flow velocity measurements 
were taken following administration of GTN at a sublingual dose of 800μg. Repeat 
haemodynamic data were taken at the same position at the proximal aortic root, at least 2 
minutes after GTN administration and when haemodynamic responses were stable. All 
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measurements were taken before the administration of ionic contrast agents for the 
subsequent angiogram or angioplasty.   
 
Study 2 Central haemodynamic response to intracoronary nitroglycerin 
Preparation and measurements of central haemodynamic response to intracoronary 
nitroglycerin were carried out as described in chapter 2. A diagnostic coronary angiogram 
was performed prior to the research study to ensure the absence of significant left main stem 
or critical left anterior descending coronary artery disease that could affect the distribution of 
nitroglycerin within the left ventricle. Baseline pressure and flow measurements were 
obtained from the Combowire in the aortic root as described above. The guiding catheter was 
then advanced to the left coronary ostium for NTG (Hospira Incorporation) infusion at 
1μg/min.  This dose was determined by previous studies that found no significant systemic 
effects when NTG 1μg/min was infused locally into the brachial artery196 and by dose 
ranging studies where intravenous NTG infusion at 3μg/min was found to be the threshold 
dose above which systemic effects on aortic waveform indices (table 3). After a 7 minute 
infusion of NTG, the guiding catheter was pulled back into the proximal aortic root and 
Combowire re-positioned in the aortic root with fluoroscopic screening used to ensure 
position of the Combowire was similar to that at baseline (this taking approximately 1 
minute). Measurements of pressure and flow were then repeated as previously described. In 4 
subjects following the placement of Combowire in the proximal aortic root for continuous 
pressure/ Doppler flow velocity measurements, a separate guiding catheter was inserted via a 
second vascular access in the contra-lateral femoral artery to simultaneously infuse NTG over 




Table 3 Haemodynamic response to intravenous NTG 1μg/min at systemic dose ranging 
studies 
Measure Baseline Nitroglycerin 1 μg/min P value 
Heart Rate (min
-1
) 63±4 68±3 0.29 
cSBP (mmHg) 139±12 137±11 0.91 
DBP (mmHg) 69±3 74±3 0.23 
MAP (mmHg) 97±5 100±5 0.70 
AIx (%) 31±6 22±5 0.41 
cSBP, central systolic blood pressure; cDBP, central diastolic blood pressure; MAP, mean 
arterial pressure; AIx, augmentation index obtained by carotid tonometry. 
 
Waveform Post-processing 
This was carried out as described in chapter 2 (Section 2.11). Aortic flow velocity waveforms 
were integrated over time and multiplied by aortic cross-sectional area (estimated from body 
surface area) to obtain a measure of stroke volume and hence cardiac output and total 
systemic vascular resistance.  
 
Statistics 
Unless where stated results are expressed as means ± SE. Changes from baseline in 
haemodynamic measures after NTG were compared using Student’s paired t-test or by 
analysis of variance for repeated measures. In the case of non-normally distributed data (heart 
rate, pulse wave velocity and FEW), a Wilcoxon signed rank test was used. All tests were 2-






Contributions of FPW and BPW to AP 
Decomposition of the aortic pressure wave demonstrated that P1 was almost entirely due to 
the FPW and that the BPW contributed only a minor component to P1 (mean contributions at 
baseline of 37.1±2.8 and 1.6±1.1 mmHg respectively, figure 11). The FPW also provided the 
major contribution to AP, although the BPW also provided a significant contribution (mean 
contributions of 15.6±2.9 and 11.0±2.8 mmHg for the FPW and BPW respectively, figure 





a) Central (aortic) pulse pressure (cPP) and the components of cPP: height of the first 
systolic shoulder above diastolic blood pressure (P1) and augmentation pressure (AP), the 




b) AP and AP decomposed into components attributable to the forward pressure wave 
(APFPW) and backward pressure wave (APBPW) before and after sublingual nitroglycerin 
(NTG, n=20).  
c) Augmentation index (AIx, the ratio of AP to cPP) and AIx decomposed into components 
attributable to the forward pressure wave (AIx FPW) and backward pressure wave (AIx BPW) 
before and after nitroglycerin (NTG, n=20). 
 
Effects of systemic NTG on haemodynamics and pulse pressure components  
Systemic administration of NTG had no significant effect on P1 but reduced AP by 12.8±3.1 
mmHg (from 26.1±3.1 to 13.3±2.6 mmHg, P<0.0001, figure 11) and reduced cSBP and cPP 
by similar amounts (from 136±5 to 127±6 mmHg and from 63.0±4.0 to 51.3±3.9 mmHg 
respectively, each P<0.01).  AIx decreased by 17.3±3.0% (from 39.5±3.6 to 22.2±5.0%, 
P<0.0001). By contrast, NTG had no significant effect on mean arterial blood pressure, total 
peripheral resistance, or on aortic PWV (table 4).  There was a non-significant trend to an 
increase in heart rate of 4 beats/min and decrease in stroke volume of borderline significance 
(table 4). The phase and modulus of the aortic input impedance did not change significantly 








Table 4 Haemodynamic changes after sublingual nitroglycerin 
cSBP, central systolic blood pressure; cDBP, central diastolic blood pressure; MAP, mean 
arterial pressure; P1, pressure at the first systolic shoulder of pressure pulse; AP, 
augmentation pressure; cPP, central pulse pressure; PWV, pulse wave velocity; TPR, total 
peripheral resistance. *These values were computed from an estimate of aortic root area 
assumed to remain constant after NTG 
 
Measure Baseline NTG Difference 95%CI P value 
Heart rate (min
-1
) 64±2 68±3 4.33± 1.43 1.34 to 7.32 0.06 
Blood pressures      
cSBP (mmHg) 136±5 127±6 -8.31±2.47 -13.5 to -3.14 <0.01 
cDBP(mmHg) 73±3 76±3 3.35±1.93 -0.686 to 7.39 0.10 
MAP(mmHg) 99±3 98±4 -0.67±2.26 -5.39 to 4.05 0.77 
Pulse pressures      
P1 (mmHg) 36.9±2.6 37.2±2.9 0.28±1.77 -3.43 to 3.99 0.21 
AP (mmHg) 26.1±3.1 14.1±2.4 -12.8±1.93 -16.9 to -8.77 <0.0001 
cPP (mmHg) 63.0±4.0 51.3±3.9 -11.7±1.50 -14.8 to -8.52 <0.0001 
Augmentation Index (%) 39.5±3.6 22.2±5.0 -17.3±3.00 -23.6 to -11.0 <0.0001 
Aortic PWV (m.s
-1
) 11.6±1.1 10.6±0.9 0.95±0.55 -2.11 to 0.203 0.57 
Stroke volume* (ml) 88.5±5.3 81.0±4.5 -7.44±3.56 -14.9 to 0.004 0.05 
Cardiac output* (L.min
-1
) 5.6±0.3 5.4±0.3 -0.17±0.26 -0.708 to 0.361 0.51 
TPR* (mmHg.L
-1





Average modulus a) and phase b) of aortic input impedance at baseline and after sublingual 
nitroglycerin (n=20).  
 
Figure 13 
Typical aortic pressure waveforms decomposed into forward and backward pressure waves at 
baseline and after nitroglycerin (NTG). The major effect of NTG is to reduce the forward 
wave after the first systolic shoulder, the time of peak systolic stress. Corresponding flow 





Effects of systemic NTG on FPW and BPW components of AP and on pressure wave intensity 
amplitudes, timings and energies 
The reduction in AP after NTG was explained by a reduction of 7.0±2.4 mmHg (from 
17.4±3.8 to 10.4± 2.9 mmHg, P<0.02) in the FPW and a reduction in the BPW of 5.8±1.3 
mmHg (from 8.6±1.9 to 2.8±1.5 mmHg, P<0.01, figures 11 and 13).  The reflection 
coefficient as defined as the ratio of the maximum amplitude of the FPW to BPW did not 
change significantly after NTG (0.28±0.02 to 0.27±0.02, P=0.410). An example of a wave 
intensity plot before and after NTG is shown in figure 14. Average values of maximum wave 
intensities, timings (of maximum intensities) and wave energies for the FCW, BCW and 
FEW before and after NTG are shown in table 4. Amplitude of the BCW but not the FCW 
decreased after NTG whereas energy of both the FCW and BCW were reduced after NTG 
and the ratio of BCW/FCW energy was unaltered. There was a small but significant reduction 
in time to the FEW after NTG but timings of other waves remained similar before and after 










Typical wave intensity plots at baseline and after NTG.  



































































































































































































































Table 5 Wave intensity analysis  
FCW, forward compression wave; FEW, forward expansion wave; BCW, backward 
compression wave   
 
Effects of intra-coronary NTG on AP  
There was no significant change in cSBP, MAP, P1 or heart rate after intra-coronary NTG (1 
μg/min for 7 min, data not shown). However intra-coronary infusion of NTG reduced AP by 
8.3±3.1 mmHg (from 27.6 ± 9.7 to 19.2 ± 8.4 mmHg, P<0.05, figure 15) and reduced AIx by 
9.3% (from 31.0± 6.5 to 21.7 ± 5.6%, P<0.05).  Effects of intra-coronary NTG on FPW and 
BPW components of AP and AIx did not reach statistical significance but there was a trend 
for a reduction in the FPW components of AP and AIx (P=0.17, and P=0.08, respectively) but 
not the BPW components of AP and AIx (P=0.50, and P =0.96).  Thus the reduction in AP 
and AIx by intra-coronary NTG was potentially explained by an effect on the FPW alone.  
















   
FCW 0.50±0.066 0.48±0.063 0.58 
FEW 0.17±0.025 0.16±0.030 0.95 
BCW 0.084±0.013 0.060±0.0091 <0.005 
BCW:FCW 0.19±0.026 0.14±0.018 <0.01 
Wave Timing (ms)    
FCW 59.0±7.43 56.5±7.07 0.33 
FEW 314±14.0 304±9.24 0.03 





)    
FCW 0.045±0.0043 0.039±0.0041 <0.001 
BCW 0.011±0.0012 0.0084±0.00094 <0.005 





Augmentation pressure and augmentation index before and after intra-coronary infusion of 
NTG (1 μg/min, n=10). 
 
4.4 Discussion 
AP accounts for the much of the inter-subject variability in cPP
71
 and an increase in AP is the 
major cause of the age-related increase in cPP.
63
 AP has, hitherto, been attributed to 
augmentation of the FPW (which determines P1) by the BPW, the BPW being attributed to 
wave reflection. However, the interpretation of AP as an index of reflection assumes that the 
FPW plateaus at P1 and has been criticised because of the poor relationship between the 
magnitude and timing of reflected waves with respect to AP.
60, 61
 Although I observed a 
significant contribution of the BPW to the AP, the major contribution to AP derived from the 
FPW with the contribution of the FPW to AP being approximately twice that of the BPW. 
79 
 
This suggests that AP is in large part independent of processes such as pressure wave 
reflection or other haemodynamic effects that may influence the BPW. 
NTG is markedly effective in reducing AP, an effect that has been attributed to 
dilation of conduit arteries and a change in magnitude and/or timing of wave reflections,
86
 In 
the present study, systemic administration of NTG at a dose that dilates conduit arteries by 
between 10 to 20% 
63
 reduced AP by more than 46%. The aortic pressure wave is determined 
by the interaction of ventricular contraction with the input impedance of the aorta and more 
distal circulation as “seen” at the aortic root (the point of pressure recording). Thus a 
reduction in AP could, in principle, result from a change in myocardial contraction/relaxation 
and/or change in input impedance. With the relatively low dose of NTG that was used, I 
observed no significant change in the modulus or phase of the impedance but there was a 
trend to a shift to the left of the phase of the impedance in keeping with previous observations 
which have been attributed to a delay in reflections.
197
 To probe the haemodynamic 
determinants of this effect of NTG on AP further, I performed waveform decomposition 
before and after NTG. The reduction in AP was only partially explained by the BPW with the 
reduction in the FPW component of AP contributing proportionately more than that of the 
BPW to the total reduction in AP. Furthermore, the ratio of the BPW to the FPW, whether 
measured as the ratio of the maximum amplitudes of the waves or as ratio of wave energy in 
FCW and BCW, did not change significantly after NTG suggesting that most of the reduction 
in the BPW was secondary to that in the FPW. 
Since P1 occurs at the time of peak systolic stress (i.e. peak contraction in individual 
myocytes) in the myocardium,
198
 the reduction of the FPW component of AP but not of P1 by 
NTG implies an earlier or more pronounced relaxation of the myocardium after peak stress. 
The observation that wave maximal wave intensity of the FCW which occurs before P1 is 
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unaltered but FCW energy which includes components after P1 during augmentation is 
reduced is consistent with a reduction of the forward wave during pressure augmentation. 
Earlier onset of the FEW is consistent with earlier onset of relaxation of the ventricle. It is 
notable that sodium nitroprusside, a NO donor thought to act through the same downstream 
cGMP effector pathway as NTG delivered locally into the coronary circulation with 
negligible systemic delivery to the peripheral circulation, hastens the onset of relaxation of 
the ventricle
159, 199
 and a similar effect is seen in isolated myocytes exposed to NO
158
 or to 
cGMP mimetics acting downstream of the NO-soluble guanylyl cyclase pathway.
199
  
To test the possibility that the effect of NTG to reduce the FPW component of AP 
relates to myocardial contraction/relaxation, NTG was injected directly into the left coronary 
circulation at a dose below that observed to generate systemic effects when given 
intravenously and approximately 50 fold lower than that used to achieve systemic effects in 
the present study (assuming bioavailability of sublingual NTG to be approximate 35%
67, 200
). 
I observed a significant, albeit less pronounced, effect on AP. This is consistent with an 
influence of NTG on the FPW component of AP through a direct action on the myocardium 
to hasten the onset of relation after P1. However, delivery of NTG through the myocardial 
circulation to the central venous return (via the coronary sinus) may result in a relatively 
greater concentration in pulmonary vessels than achieved by a systemic venous infusion and, 
as I did not measure left ventricular end-diastolic pressure or volume, I cannot be certain that 
preload was not altered by intracoronary NTG. Similarly, the reduction in pulse pressure at 
the baroreceptors brought about by NTG could result in an increase in sympathetic activity. 
Thus although my intra-coronary studies identify an action of NTG on ventricular 
contraction/relaxation dynamics independent of an action on the peripheral arterial tree, this 
could be due to direct and/or indirect actions on the myocardium. 
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Irrespective of the mechanism through which NTG acts on the myocardium, my 
results challenge the conventional view that effects of NTG to reduce AP and cPP are 
mediated mainly by a reduction in wave reflection. Instead they identify a novel mechanism 
whereby AP and cPP is influenced predominantly by the FPW and hence the 
contractility/relaxation dynamics of the myocardium. Interestingly Schultz et al have reached 
a similar conclusion regarding dominance of the FPW as responsible for change in the central 
pulse during exercise.
67, 201
 My results have implications for the age-related increase in pulse 
pressure, incidence of isolated systolic hypertension (ISH) and impaired ventricular-vascular 
coupling. Ventricular relaxation is known to decrease with age and there is a strong 
correlation between ventricular relaxation and AP.
201, 202
 This has been assumed to be due to 
the additional afterload imposed by increased AP.
201, 202
 My results raise the possibility of an 
opposite direction of causality, that changes in myocardial contraction/relaxation drive those 
in AP. Thus increased AP, cPP and ISH could result, in part, from an age-related decline in 
myocardial function with a delayed onset of relaxation. This in turn, could be due to an age-
related decline in the availability of endogenous NO from endothelial or neuronal NO 
synthase.
202, 203
 Further interventional studies will be required to explore this possibility. 
My study is subject to several limitations. By necessity the study was limited to 
subjects that had clinical indications for coronary angiography and a substantial proportion of 
these had established coronary artery disease. Thus I cannot exclude the possibility that 
results in subjects without coronary disease might differ and the results of our study cannot 
necessarily be extrapolated to younger subjects.  The interpretation of my study relies, in part, 
on wave separation theory. However, this theory relies on relatively few assumptions other 
than conservation of mass and momentum and results obtained using differing mathematical 
techniques are similar.
174
 Furthermore, the main finding of my study that AP is influenced by 
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ventricular dynamics is borne out by our intra-coronary study independent of wave separation 
analysis. Accuracy of CO and TPR measurements was limited by the estimation of aortic 
cross-sectional area but this would not affect the relative change before and after NTG. 
In conclusion, AP is determined in large part by the FPW and ventricular 
contraction/relaxation dynamics. NTG reduces AP by a reduction in the FPW resulting from 
earlier onset and/or more pronounced ventricular relaxation. The NO-pathway may present a 

















CHAPTER 5: DOMINANCE OF THE FORWARD 
COMPRESSION WAVE IN DETERMINING 
PULSATILE COMPONENTS OF BLOOD 
PRESSURE: SIMILARITIES BETWEEN 

















Pulsatile components of the aortic blood pressure waveform such as the amplitudes at the first 
(P1) and second shoulders (P2) of the waveform (figure 16) are important determinants of 
cardiovascular events.
40, 175, 204
 The extent to which they are determined by ventricular 
contraction, Windkessel/reservoir properties or other components of the impedance of the 
proximal arterial tree and reflections from the peripheral arterial tree is unclear.
23, 62, 179
 Wave 
intensity and wave separation analysis allows pressure to be separated into a forward 
component travelling from the left ventricle towards the periphery of the arterial tree and a 
backward component travelling from the arterial tree towards the ventricle.
172
 Pressure waves 
can be further categorized as compression or expansion (suction). A primary forward 
compression wave (FCW) arises from the “push” of the ventricle against the arterial tree and 
a systolic backward compression wave (BCW) from the push of the arterial tree against the 
ventricle. A mid systolic forward expansion wave (FEW) arises from the braking effect of the 
ventricle in late systole and other minor waves arise from other ventricular – vascular 
interactions (figure 16).195 The objective of the present study was to determine the relative 
contributions of forward and backward waves attributable to pressures generated primarily 
from the ventricle and arterial tree respectively to 1) changes in pulse pressure during 
modulation of cardiac contractility and arterial tone by dobutamine and norepinephrine.
205
 2) 






a) The central arterial pressure pulse with pulsatile components P1 and P2 determined by the heights 
of first and second shoulders respectively. 
b) Forward wave intensities showing the forward compression wave (FCW), mid-systolic forward 
expansion wave (FEW) and late systolic forward expansion wave (FEWls) 
c) Backward wave intensities showing backward expansion wave (BEW), mid-systolic backward 





Study 1: Effects of dobutamine and norepinephrine on haemodynamics 
Healthy volunteers (n=10, age 35-63 years, 8 male) took part in this cross-over study to 
investigate the change in pulsatile haemodynamics following inotropic/vasopressor 
stimulation. They received cumulative doses of dobutamine (Db) and norepinephrine (NE) on 
two separate visits at least 7 days apart. Measurements were performed in a quiet temperature 
controlled (24-26 ⁰C) vascular laboratory and subjects were asked to avoid caffeine and 
alcohol on the day of the study.  On arrival in the vascular laboratory a peripheral venous 
catheter was inserted into the left antecubital fossa through which  0.9% saline (Baxter 
Healthcare) vehicle or drugs dissolved in saline were infused at 1ml/minute using a syringe 
driver (Injectomat, Agilia®, Fresenius Kabi, Germany). After 30 minutes resting supine 
during infusion of saline vehicle, baseline haemodynamic measurements (carotid artery 
tonometry and aortic Doppler flow velocity measurements) were made as described in 
chapter 2. Dobutamine (2.5, 5 and 7.5 µg/Kg/min, Hameln Pharmaceuticals, UK) or 
norepinephrine (12.5, 25, 50 ng/Kg/min, Aguettant Ltd, UK) dissolved in 0.9% saline vehicle 
were then infused at 1 ml/min and haemodynamic measurements repeated at each drug dose 
after 7 minutes of infusion when steady state was achieved.  
 
Study 2 Comparison of haemodynamic measures in patients with untreated hypertension and 
normotensive controls 
Patients with untreated essential hypertension or hypertension inadequately controlled on 
treatment were recruited from the hypertension clinics at Guy’s and St Thomas’ Hospital. 
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Hypertension was diagnosed as an office blood pressure >140/90 mmHg on at least 3 
occasions and/or ambulatory blood pressure > 130/85 mmHg. Patients on treatment for 
hypertension were included if office blood pressure on treatment was > 140/90 mmHg. 
Exclusion criterion included: intercurrent illness, pregnancy, significant systemic disease 
other than mild hypertensive nephropathy, history of ischaemic heart disease, valvular heart 
disease, echocardiographic evidence of left ventricular ejection fraction <50%, regional wall 
motion abnormality, left ventricular outflow tract obstruction, pulmonary hypertension and 
poor transthoracic acoustic window. Healthy volunteers on no regular medication of a similar 
age and sex distribution to hypertensive subjects were recruited by advertisement from the 
local community. Subject characteristics are shown in table 6. Subjects were asked to avoid 
caffeine and alcohol on the day of the study.  Haemodynamic measurements were performed 
as chapter 2 Both study 1 and 2 were approved by the London Westminster Research Ethics 



















 Hypertensive patients 
(n=20) 
Age (years) 52.2±12.6 48.8±11.3 
Men (%) 85 75 
Systolic blood pressure (mmHg) 120±14.2 165±26.6
‡ 
Diastolic blood pressure (mmHg) 71.1±8.20 98.7±14.2
‡ 




Total cholesterol (mmol/L) 5.4±0.8 5.0±1.2 
High density lipoprotein (mmol/L) 1.7±0.6 1.5±0.5 
HbA1c (%) 5.5±0.2 5.8±0.5 
Drug therapy   
ACEI (%) - 25 
ARB (%) - 25 
β-blocker (%) - 15 
Calcium channel blocker (%) - 65 
Diuretic (%) - 50 
α-blocker (%) - 30 
Statins (%) - 60 




Data are means±SD or %. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker. †P<0.01 ‡P<0.005 compared to normotensive controls 
 
Haemodynamic measurements 
Radial and carotid pressure waveforms were obtained by applanation tonometry performed 
by an experienced operator (HF) using the SphygmoCor system (AtCor, Australia). 
Approximately 10 cardiac cycles were obtained and ensemble averaged. Waveforms which 
did not meet the in-built quality control criteria in the SphygmoCor system were rejected. 
Brachial blood pressure was measured in triplicate by a validated oscillometric method 
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(Omron 705CP, Omron Health Care, Japan) and used to calibrate radial waveforms to obtain 
a mean arterial pressure (MAP). Carotid waveforms were calibrated from MAP and diastolic 
brachial blood pressure on the assumption of equality of these pressures at central and 
peripheral sites.
206
 The primary analysis was performed on non-transformed carotid 
waveforms and a secondary analysis on waveforms transformed to aortic waveforms using 
the inbuilt transfer function in the SphygmoCor system. 
Ultrasound imaging was performed by an experienced operator (BJ) using the Vivid-7 
ultrasound platform (General Electric Healthcare, UK). Velocity across the aortic valve was 
recorded using continuous wave Doppler obtained from an apical 5-chamber view. Stroke 
volume (SV) was calculated from the product of velocity time integral (VTI) and cross-
sectional area of the aortic valve (obtained in the parasternal long axis view). All 
measurements were averaged over at least 3 cardiac cycles.  Cardiac output (CO) was 
calculated from SV and heart rate and total peripheral resistance (TPR) from mean arterial 
pressure (MAP) divided by CO.  
 
Waveform post-processing 
This was carried out as described in chapter 2. 
 
Statistical Analysis 
Subject characteristics are summarized as means±SD and results as means±SEM. Differences 
between haemodynamic measures in hypertensive and normotensive subjects were examined 
using Student’s unpaired t-test. Responses to the vasoactive drugs relative to baseline were 
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sought by repeated-measures ANOVA. P<0.05 was considered significant, and all tests were 
2 tailed. Analysis was performed using SPSS version 19. 
 
5.3 Results 
Effects of dobutamine and norepinephrine on pressure wave components and wave intensities 
The major effect of dobutamine was to increase CO and pulsatility (particularly P1), this 
being associated with a trend to an increase in MAP and decrease in TPR (table 7). 
Norepinephrine increased TPR and MAP and also P2 and AP but not P1 (table 8). There was 
















Table 7 Haemodynamic changes during infusion of dobutamine 
  Dobutamine (µg/kg/min) 
Measure Baseline  2.5  5  7.5 








pDBP (mmHg) 65.9 ± 2.88 65.5 ± 2.57 66.2 ± 2.28 67.2 ± 1.98 
MAP (mmHg) 80.3 ± 3.48 82.0 ± 3.25 85.1 ± 2.57 87.9 ± 2.04 
HR (bpm) 64.7 ± 3.51 66.7 ± 4.51 69.0 ± 4.74 73.0 ± 5.24† 


















AP (mmHg) -4.29 ± 2.46 -5.73 ± 2.84 -9.91 ± 3.82
 
-11.8 ± 4.48 




TPR(mmHg·min/L) 12.0 ± 0.925 11.4 ± 0.928 10.7 ± 0.694 10.2 ± 0.999 
PWV (m/s) 4.07 ± 0.402 4.52 ± 0.371 5.10 ± 0.391 5.58 ± 0.31
†
 







)    
FCW 1.42 ± 0.226 2.17 ± 0.267 3.05 ± 0.348 3.65 ± 0.434‡ 
FEW 0.137 ± 0.0452 0.140 ± 0.0452 0.193 ± 0.0399 0.243 ± 0.0614 
FEWls 0.128 ± 0.0235 0.181 ± 0.0357 0.168 ± 0.0273 0.339 ± 0.0955
* 




BCW -0.0200 ± 0.00505 -0.0409 ± 0.00835 -0.0468 ± 0.00833
 
-0.0399 ± 0.0136 
BCWls -0.0472 ± 0.0120 -0.0471 ± 0.0133 -0.0982 ± 0.0267 -0.164 ± 0.0390
† 
BCW:FCW 0.0188 ± 0.00632 0.0201 ± 0.00380 0.0171 ± 0.00402 0.0161 ± 0.00468 
     
Wave Timing (ms)     




FEW 199 ± 30.5 195 ±28.4 190 ± 23.4 152 ± 28.4 
FEWls 332 ±21.3 326 ±24.8 298 ±17.2 281 ± 20.4 
BEW 71.1 ± 13.0 91.4 ± 7.09 82.8 ± 11.3 67.2 ± 12.0 
BCW 206 ± 19.7 224 ± 21.9 195 ± 10.8 118 ± 29.8
‡ 
BCWls 334 ± 22.7 340 ± 17.6 297 ± 16.6 257 ± 32.9 
Data are expressed as means ±SEM; AP, augmentation pressure; BCW, mid systolic backward compression wave; 
BCWls, late systolic backward compression wave; BEW, backward expansion wave; CO, cardiac output; cSBP, 
central systolic blood pressure; FCW, forward compression wave; FEW, mid systolic forward expansion wave; 
FEWls, late systolic forward expansion wave; HR, heart rate; MAP, mean arterial pressure; P1, pressure at first 
systolic shoulder; P2, pressure at second systolic peak;  pSBP, peripheral systolic blood pressure; pDBP, peripheral 
diastolic blood pressure; PWV, pulse wave velocity; TPR, total peripheral resistance. *P<0.05, †P<0.01, ‡P<0.005 
repeated measures ANOVA for dose response curve. 
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Table 8 Haemodynamic changes during infusion of norepinephrine 
  Norepinephrine (ng/kg/min) 
Measure   Baseline 12.5 25 50 
pSBP (mmHg) 114 ± 4.43 117 ± 4.56 120 ± 3.97 126 ± 4.01
† 
pDBP (mmHg) 67.1 ± 2.31 69.1 ± 2.62 73.4 ± 2.82 78.4 ± 2.84
‡
 
MAP (mmHg) 80.3 ± 3.48 82.0 ± 3.25 85.1 ± 2.57 94.3 ± 3.22‡ 
HR (bpm) 61.5 ± 2.89 57.7 ± 2.91 55.2 ± 2.81 52.7 ± 2.63
†
 
cSBP (mmHg) 103 ± 4.90 109 ± 5.01 111 ± 5.05 123 ± 6.29
‡
 
P1 (mmHg) 35.5 ± 1.67 36.5 ± 2.05 33.1 ± 2.72 36.8 ± 2.84 
P2 (mmHg) 33.0 ± 2.66 35.8 ± 3.18 37.3 ± 2.72 43.7 ± 4.31‡ 
AP (mmHg) -2.45 ± 2.39 -0.664 ± 2.43 4.26 ± 2.19 6.92 ± 3.29
‡
 
CO (L/min) 6.36 ± 0.328 5.99 ± 0.327 5.64 ± 0.152 5.13 ± 0.240
‡
 
TPR(mmHg·min/L) 13.2 ± 0.908 14.6 ± 1.13 16.0 ± 0.606 19.2 ± 1.38
‡
 
PWV (m/s) 4.35 ± 0.286 4.71 ± 0.464 4.68 ± 0.163 5.55 ± 0.598 







)     
FCW 1.03 ± 0.104 1.01 ± 0.0729 0.803 ± 0.104 0.867 ± 0.114 
FEW  0.0990 ± 0.0327 0.149 ± 0.0315
 
0.105 ± 0.0216 0.162 ± 0.0396
 
FEWls 0.115 ± 0.0404 0.115 ± 0.0282 0.123 ± 0.0343 0.0971 ±0.0182 
BEW -0.0215 ± 0.00550 -0.0410 ± 0.0107 -0.0357 ± 0.0104 -0.0363 ± 0.00642 
BCW -0.0187 ± 0.00417
 
-0.0310 ± 0.00633 -0.0308 ± 0.00661 -0.0357 ± 0.00827* 
BCWls -0.0547 ± 0.0171 -0.0540 ± 0.0103 -0.0543 ± 0.0133 -0.0465 ± 0.00956 
BCW:FCW 0.0191 ± 0.00272 0.0317 ± 0.00662 0.0383 ± 0.00901 0.0428 ± 0.00887* 
     
Wave Timing (ms)     
FCW 37.5 ± 1.04 35.9 ± 1.28 37.5 ± 1.04 38.3 ± 0.781 
FEW 202 ± 32.6 256 ± 25.5 243 ± 35.5 304 ± 19.7 
FEWls 333 ± 24.9 381 ± 18.9 381 ± 17.9 427 ± 21.2
† 
BEW 93.0 ± 12.4 105 ± 8.25 96.9 ± 8.09 93.0 ± 7.22 
BCW 192 ± 30.6 224 ± 18.0 234 ±18.8 234 ± 21.7 
BCWls 307 ± 38.6 334 ± 23.1 387 ± 13.0 402 ± 29.1 
Data are expressed as means ±SEM; AP, augmentation pressure; BCW, mid systolic backward compression wave; BCWls, 
late systolic backward compression wave; BEW, backward expansion wave; CO, cardiac output; cSBP, central systolic 
blood pressure; FCW, forward compression wave; FEW, mid systolic forward expansion wave; FEWls, late systolic 
forward expansion wave; HR, heart rate; MAP, mean arterial pressure; P1, pressure at first systolic shoulder; P2, pressure 
at second systolic peak;  pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood pressure; PWV, pulse 






Whilst dobutamine increased pulsatility, increasing both P1 and P2 it did so by increasing the 
forward pressure wave, with no significant contribution of the backward wave to the increase 
in P2 (figures 17, 18 and 19). Dobutamine increased the FCW and also the late systolic FEW, 
BEW and late systolic BCW. However there was no significant change in the ratios of the 
secondary waves to the FCW. Norepinephrine tended to increase the backward component of 
P2, particularly in subjects with a positive AP (figures 17, 18 and 19) and, by contrast to 
dobutamine, increased the mid systolic BCW both in absolute terms and as a proportion of 





Typical pressure pulses decomposed into forward (dashed) and backward (dotted) 





Pressure pulse components showing total pressure pulse and forward (Fw) component of 





Pressure pulse components showing total pressure pulse and forward (Fw) component of 




However, the forward wave remained the major component of both P1 and P2 during 
stimulation with norepinephrine. When using transformed carotid waveforms, there were 
modest but significant differences in absolute pressures from those obtained from the non-
transformed waveform (table 9). However, the main findings that majority of the pulse 
pressure components during stimulation with both dobutamine and norepinephrine derive 
from the forward pressure wave remained unchanged. 
Table 9:  Forward and backward pulse pressure  components determined using non-
transformed and transformed carotid waveforms 
Measure Baseline Db 7.5μg/kg/min Baseline NE 50ng/kg/min 
Non-transformed     
P1(mmHg) 36.8±3.74 59.0±3.41 35.5±1.67 36.8±2.84 
P1f (mmHg) 36.1±3.81 56.9±3.14 34.5±1.61 36.5±3.05 
P1b (mmHg) 0.670±0.233 2.08±0.50 0.989±0.509 0.237±0.982 
P1f (%) 98.0±0.709 96.6±0.797 97.3±1.31 99.4±2.40 
P1b (%) 2.00±0.709 3.36±0.797 2.69±1.31 0.588±2.40 
P2 (mmHg) 32.5±3.02 47.2±3.17 33.0±2.66 43.7±4.31 
P2f (mmHg) 31.6±3.35 48.9±3.24 31.7±2.75 39.9±3.41 
P2b (mmHg) 0.88±1.52 -1.66±2.08 1.27±1.54 3.82±2.10 
P2f (%) 97.3±3.65 105±5.55 96.1±4.18 92.4±4.22 











P1f (mmHg) 29.7±3.09† 46.2±2.94† 28.5±1.33† 30.8±2.53† 
P1b (mmHg) 0.219±0.182
†










 1.56±1.60 -2.89±2.68 


























Data are means ±SEM; P1, pressure at first systolic shoulder; P1f forward pressure wave at P1; P1b 
backward pressure wave at P1; P2, pressure at second systolic peak; P2f forward pressure wave at P2; P2b 
backward pressure wave at P2; *P<0.05, †P<0.01 for comparison between wave separation analysis 
indices using carotid pressure pulse versus synthesized aortic pressure pulse. 
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Comparison of haemodynamic measures in patients with untreated hypertension and 
normotensive controls 
Compared to normotensive subjects, hypertensive subjects were characterized by increased 
MAP and increased central aortic pulsatility with P1, P2 and AP and increased by 11.8±2.8, 
24.3±4.8 and 12.5±3.8 mmHg respectively compared to normotensive subjects. P1 and P2 
were of approximately equal magnitude in normotensive subjects so that AP was close to 
zero. However, in hypertensive subjects, P2 exceeded P1 giving an AP of 12.6±3.5 mmHg. 
TPR was greater in hypertensive compared to normotensive subjects but CO was similar in 















Table 10   
Measure Normotensive controls Hypertensive patients 
pSBP (mmHg) 120 ± 14.2 165 ± 26.6‡ 
pDBP (mmHg) 71.1 ± 8.20 98.7 ± 14.2‡ 
MAP (mmHg) 87.3 ± 1.97 122 ± 3.38
‡ 
HR (bpm) 63.0 ± 1.66 66.2 ± 2.14 
cSBP (mmHg) 109 ± 2.67 159 ± 5.06
‡ 
P1 (mmHg) 33.9 ± 1.67 45.7 ± 2.26‡ 
P2 (mmHg) 34.1 ± 2.13 58.4 ± 4.35
‡
 
T1 (ms) 106 ± 2.97 99.6 ± 3.34 
T2 (ms) 221 ± 4.02 211 ± 5.79
 
AP (mmHg) 0.133 ± 1.58 12.6 ± 3.49
 ‡
 
CO (L/min) 5.30 ± 0.306 5.98 ± 0.404
 
TPR (mmHg·min/L) 17.9 ± 1.41 22.7 ± 1.95* 








FCW 0.92 ± 0.0779 1.50 ± 0.118
*
 
FEW 0.143 ± 0.0171 0.267 ± 0.0343
‡ 
FEWls 0.0860 ± 0.0151 0.163 ± 0.0192
†
 
BEW -0.0403 ± 0.00666 -0.0562 ± 0.00938 
BCW -0.0242 ± 0.00478 -0.0904 ± 0.0226
*
 
BCWls -0.0460 ± 0.00942 -0.0575 ± 0.0112 
BCW:FCW 0.0296 ± 0.00659 0.0573 ± 0.00765
‡
 
Wave Timing (ms) 
FCW 36.3 ± 1.03 39.5 ± 1.20 
FEW 255 ± 18.4 257 ± 13.5 
FEWls 389.5 ± 13.9 374 ± 16.0 
BEW 96.5 ± 4.98 81.6 ± 5.8 




BCWls 353 ± 22.3 346 ± 12.2
 
Data are expressed as means ±SEM; AP, augmentation pressure; BCW, mid systolic 
backward compression wave; BCWls, late systolic backward compression wave; BEW, 
backward expansion wave; CO, cardiac output; cSBP, central systolic blood pressure; 
FCW, forward compression wave; FEW, mid systolic forward expansion wave; 
FEWls, late systolic forward expansion wave; HR, heart rate; MAP, mean arterial 
pressure; P1, pressure at first systolic shoulder; P2, pressure at second systolic 
shoulder; pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood 
pressure; PWV, pulse wave velocity; TPR, total peripheral resistance; T1, time of P1 
after onset of systole; T2, time of P2 after onset of systole. *P<0.05, †P<0.01, 




Relative contribution of forward and backward waves to pulsatile components of blood 
pressure in normotensive and hypertensive subjects 
Wave separation analysis demonstrated that, in normotensive subjects, both P1 and P2 were 
determined almost exclusively by forward components of the pressure wave, although in 
subjects with a positive AP, the backward wave did contribute to P2. In hypertensive subjects 
(in whom AP was positive), P1 was also determined by the forward wave and the forward 
wave provided the major contribution to P2. However, the backward wave provided a greater 
contribution to P2 than in normotensive subjects (7.3±1.9 mmHg compared to 1.0±0.7 mmHg 
in normotensive subjects, P<0.01, figure 20) and contributed 7.1±2.1 mmHg to the total AP 





Pressure pulse components showing total pressure pulse and forward (Fw) component of pressure 




Wave intensities in normotensive and hypertensive subjects 
The FCW was greater in hypertensive compared to normotensive subjects (table 10). The mid 
systolic BCW was also greater in hypertensive compared to normotensive subjects, both in 
absolute terms and as a proportion of the FCW and tended to arrive earlier in systole in 
hypertensive compared to normotensive subjects, although the difference in timing was not 
statistically significant (table 10). The FEW were also greater in hypertensive compared to 




Temporal variation of blood pressure during systole offers not only an insight into 
ventricular-vascular interaction but contributes to the risk of future cardiovascular events. At 
any age, pulse pressure provides additional prognostic information over MAP, and in older 
subjects, is the single most important component of blood pressure in determining 
outcome.
175
 Central (aortic or carotid) pressures generated at the interface between the 
ventricle and arterial tree propagate along the arterial tree to determine peripheral blood 
pressure and appear to be at least as important a determinant of outcome as peripheral 
pressures.
47
  In addition to central pulse pressure, the difference between P1 and P2 as 
expressed by AP or augmentation index may be an independent determinant of outcome.
47
 
Despite the importance of P1 and P2, the properties of the ventricle and arterial tree that 
generate increased pulsatility are still poorly understood. Previous studies have focused on 
central pulse pressure (equal to P2 in older subjects and P1 in younger subjects) and the 
established view is that an elevated pulse pressure in hypertension results from increased 
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augmentation of the forward pressure wave by the backward wave, this in turn arising from 
increased amplitude and/or earlier return of the backward wave.
18, 179
 An alternative view is 
that increased pulse pressure results from increased aortic characteristic impedance (which 
has greater dependence than PWV on aortic cross-sectional area) and relates, in part, to an 
effective decrease in aortic diameter.
181
  
 To my knowledge, this is the first study to use wave separation analysis to make 
direct estimates of the contributions of the forward and backward waves to pulsatile 
components of central blood pressure at rest and during modulation of pulsatility using 
dobutamine and norepinephrine, drugs that both have inotropic properties but which have 
divergent actions on the peripheral arterial tree and produce markedly different effects on 
pulse pressure and peripheral resistance. At rest, in normotensive individuals, both P1 and P2 
pulsatile components were determined almost exclusively by the forward pressure wave. 
Dobutamine produced a marked increase in both P1 and P2 that was again almost exclusively 
due to effects on the forward wave, as would be expected from an inotrope increasing 
contractility of the ventricle from which the forward wave derives. By comparison to 
dobutamine, norepinephrine produced a greater increase in MAP but only a modest increase 
in pulse pressure (determined by an increase in P2) for which forward and backward 
components were approximately equal. These results suggest, therefore, that the contribution 
of the backward wave to pulsatile components of blood pressure in normotensive subjects at 
rest and during inotropic and vasopressor stimulation is minor in comparison to that of the 
forward wave. Wave intensity analysis provides further insight into the haemodynamic origin 
of forward and backward waves. This analysis confirms that the increased forward pressure 
wave components of P1 and P2 generated by dobutamine acting to increase myocardial 
contractility result from an increased FCW which also occurs earlier in systole.  Interestingly 
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Schultz et al have reached a similar conclusion regarding dominance of the FPW as 
responsible for change in the central pulse during exercise
67
, a physiological stimulus to 
increased myocardial contractility. Changes in other waves (backward expansion, late 
systolic FEW and late systolic BCW) could be secondary to the greater intensity and earlier 
timing of the FCW.   
By contrast to dobutamine, norepinephrine did not increase the FCW. Although the 
intrinsic action of norepinephrine on the myocardium is to increase contractility, its action on 
the peripheral vascular tree to increase peripheral resistance will depend on basal sympathetic 
tone and can result in a reflex decrease in sympathetic output, myocardial contractility and a 
decrease in CO (as seen in the present study).
207
 Thus the lack of effect of norepinephrine on 
the FCW is expected. Norepinephrine did increase the mid systolic BCW both in absolute 
terms and as a proportion of the FCW, an action consistent with increased reflection that 
would be expected to increase the backward pressure wave. However, quantitative analysis of 
the relative contributions of forward and backward waves shows the contribution of the latter 
to increased pulsatility is minor. 
  
In hypertensive subjects, both P1 and P2 components were greater than in 
normotensive subjects. As in normotensive subjects, P1 was determined exclusively by the 
forward wave component. P2 was determined by both the forward and backward waves. 
However, the forward wave accounted for the majority of P2 and approximately two thirds of 
the total difference in P2 between hypertensive and normotensive subjects. The backward 
wave was a significant component of AP in hypertensive subjects, but even for AP, the 
backward wave only accounted for approximately 50% of AP.  Wave intensity analysis 
confirmed a greater FCW and mid systolic BCW in hypertension compared to normotensive 
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subjects consistent with the relative contribution of forward and backward waves to 
pulsatility. Comparison of the difference between hypertensive and normotensive subjects 
with the results of inotropic and vasopressor stimulation in normotensive subjects, show that 
increased pulsatility in hypertension most closely resembles that simulated with dobutamine 
in normotensives. These results, therefore, challenge the view that increased pulsatility in 
essential hypertension results from increased wave reflection. Instead they underline the 
dominance of the forward wave generated by ventricular contraction. Increased sympathetic 
activation is invariably present in essential hypertension and either alone or in combination 
with increased pre-load may explain increased ventricular ejection early in systole and hence 
increased forward wave components of pulsatility in hypertension.
208
  
  This study is subject to a number of limitations. The majority of the hypertensive 
subjects I studied were on treatment with diuretics and/or vasodilator drugs which would tend 
to increase sympathetic activity.  Thus, although sympathetic activation is thought to be an 
early event in the pathogenesis of hypertension
208
 I cannot be certain that these results apply 
to untreated hypertension. It is likely that the relative contribution of FCW and BCW 
components to increased pulsatility differ across the spectrum of essential hypertension and 
further studies will be required to determine the relative importance of these components 
according to age, neuro-endocrine profile and blood pressure treatment. Errors in our analysis 
could relate to non-invasive derivation of pressure and flow and the use of carotid pressure as 
a surrogate for aortic pressure. However, scaling errors relating to the exact point at which 
flow velocity is measured do not influence wave intensity values or wave separation analysis. 
We also obtained similar findings relating to the dominance of the forward pressure wave 
irrespective of whether we used a carotid-to-aortic transfer function. Furthermore, the use of 
the inotropic and vasopressor drugs to verify that the FCW arises primarily from myocardial 
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contractility and the BCW from vasoconstriction of the arterial tree strongly support the 
conclusions from these analyses.  
 
5.5 Conclusion 
An increase in pulse pressure is the major haemodynamic change contributing to 
hypertension in an ageing population. It could result from either an increase in a forward 
compression wave generated by the ventricle or backward compression wave generated from 
the arterial tree. The present results suggest that the former dominates both during inotropic 
stimulation with dobutamine and in subjects with treated essential hypertension. Even when 
arterial tone is increased with norepinephrine, the contribution of the backward wave to 
increased pulsatility is relatively modest. The results highlight the potential importance of 
ventricular dynamics as well as arterial stiffness in the genesis of systolic hypertension and 
suggest interventions that might modify this may be particularly effective in reducing pulse 
pressure and systolic hypertension. In conclusion, wave separation and intensity analysis 
suggest increased pulsatile components of blood pressure in essential hypertension derive 
predominantly from a forward pressure wave generated by increased myocardial contractility. 
An increased backward wave does contribute to increased central pulse pressure in 
hypertension but its contribution is less than predicted from augmentation pressure which is 



















The first part of this thesis systematically examined the effects of vasodilators on 
large muscular arteries and resistance arterioles in the human forearm circulation. The 
relationship between arterial diameter and PWV was also explored in order to examine 
whether modulation of PWV is due to a change in arterial diameter or is determined by a 
specific molecular pathway. For a given change in resistance arteriolar vascular tone, the NO 
donors GTN and NP acting on the NO-sGC-cGMP pathway were shown to have the most 
selective action on the radial artery, an example of a muscular large artery. By contrast 
vasodilators acting on the L-type voltage-dependent calcium channels, α-adrenoceptors and 
BNP-pGC pathways had relatively little effect on the radial artery suggesting that their 
contribution to resting vascular tone of muscular large arteries is minimal. Both sGC and 
pGC produce cGMP in VSMC, so it is unclear why BNP and NO donors should have a 
differential effect on VSMC in large muscular arteries and resistance arterioles. One possible 
explanation is the spatial compartmentalization of cGMP production within VSMC where 
sGC is thought to produce cGMP nearer to the sarcolemma compared to cGMP produced by 
pGC.
182, 183
 It is also possible that cGMP is not the only mechanism producing VSMC 
relaxation in muscular large arteries. This is supported by the observation that GTN and NP, 
both acting on the sGC-cGMP pathway, have different effects on large muscular arteries and 
resistance arterioles. An intermediate metabolite of GTN and NP and/or activation of other 
mechanisms such as endothelial hyperpolarizing factors could potentially explain the 
differential effects of NO donors on large muscular arteries.
154
  
One of the limitations of this in vivo human forearm circulation model is the difficulty 
to control for local exposure to vasoactive substances as a result of dynamic changes to 
vascular tone and blood flow, which may have confounding effects on the results of these 
studies. At present there is no obvious solution to this other than to confirm these findings 
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with in vitro experiments. Within the limits of this however, the same human forearm 
circulation model could be used to further elucidate the regulation of vascular tone in 
muscular arteries. Firstly co-infusion of NO donors and phosphodiesterase V inhibitors/sGC 
activators could be used to examine the importance of cGMP in the vascular tone of muscular 
large arteries and resistance arterioles. Secondly, the contribution of other known signaling 
pathway such as endothelin, angiotensin II, prostaglandin and potassium channels could be 
explored systematically by local infusion of agonist/antagonists. The regulation of vascular 
tone in hypertensive subjects may differ from that in healthy normotensive volunteers and 
this should be explored. A further finding from chapter 3 was the close relationship between 
arterial diameter and PWV, irrespective of the vasoactive substance used to modulate arterial 
tone. This suggested that short-term alteration in PWV is mostly dependent on change in 
vascular tone rather than dependent on a specific signaling pathway. Partitioning the 
components of PWV using the Moens-Korteweg equation demonstrated the complex 
interactions between structural proteins and VSMC in determining arterial wall stiffness and 
PWV. The paradoxical increase in elastic modulus with vasodilatation is likely an important 
property in the maintenance of arterial wall structural integrity over a wide range of vascular 
tone and pressure. 
GTN, the drug found to be the most selective dilator of large muscular arteries in 
chapter 3, is also the drug thought to be most specific in reducing AP and hence cPP. This is 
entirely consistent with an action to dilate muscular arteries and hence reduce pressure wave 
reflection from peripheral arteries – the generally accepted explanation for this action. 
However, the effect could also be due to an action on the myocardium. In chapter 4 I 
explored central haemodynamic effects of GTN during simultaneous invasive measurements 
of aortic pressure and flow velocity. This allows wave separation and wave intensity analyses 
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to be applied to test the hypothesis that reduction in the amplitude and delay in timing of 
reflected pressure waves is the main mechanism through which GTN reduces AP and cPP. In 
the first part of this study GTN was administered systemically via the sublingual route and in 
the second part of this study GTN was infused locally into the coronary arteries in order to 
examine the contribution of left ventricular dynamics on AP. At baseline wave separation 
analysis showed that the FPW provided a greater contribution to AP relative to the BPW than 
previously thought. Following sublingual administration of GTN, cPP and AP but not MAP 
or DBP were reduced, consistent with previous data in the literature.
86, 116, 146
 Application of 
wave separation and wave intensity analyses further revealed the reduction in AP was due to 
a reduction in both FPW and BPW and the ratio of BPW:FPW and BCW:FCW energy were 
unaltered suggesting most of the changes in BPW were secondary to a change in FPW. This 
surprising finding is not consistent with a reduction in wave reflection as the mechanism by 
which GTN reduces AP. Further analysis of the FPW by wave intensity analysis suggested an 
earlier and more pronounced relaxation of the left ventricle following administration of 
sublingual GTN. Firstly, the timing of FEW was shortened, which is consistent with an 
earlier onset of the ‘braking effect’ or relaxation of the left ventricle. Secondly, the maximal 
FCW wave intensity, which occurred in early systole at peak myocardial stress, remained 
relatively constant but FCW energy, which is an integral of wave peak that also includes 
waves at late systole, was significantly reduced indicating that FCW was diminished at the 
time of pressure augmentation.  
In the second part of the study infusion of intracoronary GTN at a dose that does not 
have systemic effects was used to confirm that reduction of AP by GTN is mediated, at least 
in part, by an action on the myocardium. Intracoronary GTN reduced AP despite no 
significant change in heart rate, DBP or MAP. Taken together these observations suggest that 
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at doses of GTN where DBP and MAP are unaltered, the reduction in AP and cPP is 
secondary to a direct lusitropic effect on the left ventricle. This challenges the established 
view that vasodilatation of large muscular arteries and consequent reduction of pressure wave 
reflection is the main mechanism by which GTN reduces AP and cPP. Furthermore, it adds to 
the body of evidence against the conventional view that AP and AIx are measures of pressure 
wave reflection.
61, 68, 98
 Results from this study suggest that AP is more closely related to left 
ventricular contraction/relaxation dynamics rather than the arterial load imposed on the left 
ventricle. The sensitivity of AP to GTN suggests that endogenous production of NO within 
the myocardium may be an important determinant of ventricular relaxation.
202, 203
 Further 
studies are required to probe the relationship between lusitropy and AP. In addition dose 
ranging studies with intracoronary GTN infusion with the inclusion of left ventricular 
pressure-volume loop analysis will be helpful to elucidate the role of pre-load and to confirm 
the threshold for which GTN exerts a direct effect on the myocardium.  Furthermore local 
intracoronary infusion of comparator drugs that have opposing effects to GTN on the 
vasculature and the left ventricle such as phentolamine or esmolol may be helpful in 
determining how different stimuli affect AP and also to investigate whether lusitropy 
associated with AP reduction is determined by a specific signaling pathway(s).
159, 209, 210
 
With the unexpected finding in chapter 4 that AP relates predominantly to the FPW, 
rather than the BPW, I questioned the established view that increased pulse pressure in 
hypertension relates primarily to increased arterial stiffness and increased pressure wave 
reflection. The objective of chapter 5 was to explore the relative contribution of FPW and 
BPW to cPP and its components in healthy volunteers under pharmacological stress, and also 
in subjects with hypertension and elevated pulse pressure. Wave separation and wave 
intensity analyses were again applied to examine in detail the contribution of FPW and BPW 
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to cPP and its components. Dobutamine markedly increased pulsatility, increasing cPP and its 
components, P1 and P2 without any significant effect on MAP. Most of this increase in 
pulsatility was attributable to an increase in FPW. Moreover the magnitude of increase was 
greater for P1 than in P2 resulting in a trend for a reduction in AP. Wave intensity analysis 
showed that FCW intensity increased and occurred earlier in systole with incremental doses 
of dobutamine but the BCW: FCW ratio did not change significantly, which is consistent 
with the findings that inotropic stimulation with dobutamine determines the FPW in both P1 
and P2, which in turn increases cPP. By contrast norepinephrine also increased cPP but to a 
smaller magnitude in comparison to dobutamine and with an increase in MAP. Increase in 
pulsatility was attributed to an increase in P2 but not P1, resulting in a significant rise in AP. 
Despite a significant increase in BPW with incremental doses of norepinephrine the FPW 
remained the dominant contributor to P1, P2 and cPP. In the second part of this study, cPP 
and its components were compared in hypertensive subjects and age-matched healthy 
normotensive volunteers. For both groups of subjects wave separation analysis illustrated that 
the FPW provided the dominant contribution to both P1 and P2, but in subjects with 
hypertension, the relative contribution of the BPW to P2 was higher in comparison to 
normotensive volunteers. Approximately 50% of AP was accounted for by the FPW. 
Although CO was similar in the two groups, wave intensity analysis showed that both FCW 
and FEW were significantly higher in subjects with hypertension. In addition, the BCW and 
BCW:FCW ratio were also significantly increased suggesting that in subjects with 
hypertension and elevated pulse pressure both FPW and BPW contributed to pulsatility but 
the former predominates. In comparison to inotropic and vasopressor stimulation by 
dobutamine and norepinephrine, the increase in pulsatility in hypertension resembled the 
combined effect of both drugs but the contribution of BPW to pulsatility is less than 
previously thought.  
113 
 
Taken together, the results of chapters 4 and 5 represent a paradigm shift in the 
haemodynamic genesis of hypertension. Because CO is generally similar in hypertensive and 
normotensive subjects, hypertension has traditionally been regarded as an arterial problem, 
with diastolic hypertension being due to an increase in peripheral resistance and an increased 
pulsatility and hence systolic pressure being due to increased arterial stiffness and/or 
increased pressure wave reflection. The findings from chapters 4 and 5 suggest that 
hypertension results in large part from altered ventricular dynamics. Chapter 4 highlights a 
novel potential therapeutic mechanism for reducing the ventricular generated FPW and hence 
pulse pressure via an action on lusitropy. This might be a particularly important therapeutic 
approach in subjects with isolated systolic hypertension but relatively normal arterial 
stiffness. In these subjects conventional vasodilator therapy will reduce systolic pressure in 
parallel with diastolic pressure reducing myocardial perfusion pressure and, especially in the 
presence of obstructive coronary disease, jeopardizing myocardial perfusion. By contrast, a 
drug such as GTN with preferential effects to reduce systolic but not diastolic pressure 
through a lusitropic action may confer greater benefit for a given degree of systolic blood 





The major findings from this thesis challenge the conventional view that widened pulse 
pressure is predominantly driven by pressure wave reflection resulting from increased arterial 
stiffness. Instead experimental results from both chapters 4 and 5 of this thesis showed that 
left ventricular contraction/relaxation dynamics has a major influence on pulsatility. This has 
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a strong translational potential for the therapeutic development for ISH and perhaps also for 
heart failure with preserved ejection fraction. The application of wave intensity analysis to 
studies using pharmacological probes, in addition to left ventricular pressure-volume loop 
analysis could further our understanding between left ventricular contraction/relaxation 
dynamics and pulse pressure. In this regard the nitric oxide donors appear to be the most 
promising but a number of important questions pertaining to their effects on preload and the 
contribution of other known signaling pathway such as the renin-angiotensin-aldosterone 
system should be systematically explored. Furthermore the haemodynamic changes induced 
by pharmacological probes in the presence of left ventricular hypertrophy and diastolic 
dysfunction will be of much interest as it will shed light on the haemodynamic effect of 
ventricular stiffening. Patients with hypertrophic cardiomyopathy in the absence of coronary 
artery disease and hypertension would be an interesting group of subjects to investigate for 
this matter. Finally the differential vasoregulatory mechanisms of muscular conduit arteries 
and resistance arterioles should be explored further in hypertensive patients to determine the 
effect of arterial disease on the resting tone of muscular conduit arteries. 
 
Conclusion 
This thesis was set out to determine the mechanism by which vasodilators reduce AP and 
cPP. The major findings of this thesis were (i) NO donors have a selective action to dilate 
large muscular arteries relative to resistance arterioles. (ii) Despite this action on large 
muscular arteries, the major action of GTN to reduce AP and cPP is mediated by a novel 
direct lusitropic mechanism on the left ventricle, rather than a reduction in pressure wave 
reflection. (iii) Both FPW and BPW contribute to the increase in AP and cPP in hypertension. 
However most of the increase in pulsatility is mediated through altered ventricular 
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contractility. Further research is required to investigate the relationship between ventricular 
dynamics, lusitropy in particular, and pulse pressure and the signaling pathway(s) that 
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